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A recent study links N-terminal acetylation and N-end rule
degradation to blood pressure regulation. N-terminal
mutants of Rgs2, a key G-protein regulator, are differen-
tially processed by N-terminal acetyltransferases and the
two branches of the N-end rule pathway. This leads to
an imbalance in the signaling governing blood pressure.
N-terminal acetylation (Nt-acetylation) and N-end rule
degradation (see Glossary) was recently linked to blood
pressure regulation. A tightly regulated G-protein signal-
ing pathway molecularly controls blood pressure through
vasoconstriction [1]. Rgs2, an important regulator of this
signaling, is now shown to be subjected to N-terminal
acetylation followed by N-end rule mediated degradation.
Nt-acetylation represents one of the most common pro-
tein modifications in eukaryotes. In humans and other
mammals, Nt-acetylation is catalyzed by six N-terminal
acetyltransferases (NATs), NatA-NatF. Numerous studies
found functional implications of Nt-acetylation [2], includ-
ing modulation of subcellular localization and protein-
protein interactions. Hwang and Varshavsky made a
breakthrough in this field by showing that an Nt-acetyl
group can decrease the half-life of a protein, thereby sug-
gesting a fundamental function of Nt-acetylation [3].
The N-end rule relates the half-life of a protein to its
N-terminal sequence, particularly to the identity of its
N-terminal residue [4]. In 2010, Hwang and colleagues
revealed a surprising connection between the N-end rule
and Nt-acetylation. They discovered that specific N termini
(starting with Met, Ser, Ala, Thr, or Val) previously
thought to confer long half-lives were in fact destabilizing
if they were modified by Nt-acetylation [3]. This work
provided the first characterization of the Ac/N-end rule
pathway and in addition to describing the aforementioned
acetylated N termini as Ac/N-degrons, it also identified
an Ac/N-recognin, Doa10. Ac/N-recognins are E3 ubiquitin
ligases targeting proteins harboring an Ac/N-degron for
proteasomal degradation. Proteins that do not bear the Nt-
acetyl group and contain specific destabilizing N-terminal
residues can be targeted for proteasomal degradation by
the previously discovered branch of the N-end rule path-
way, termed the Arg/N-end rule pathway [4].
Together, the set of proteins proposed as targets of these
degradation pathways encompass a large fraction of the
proteome. It may seem strange that the bulk of proteins
would be co-translationally targeted for degradation. How-
ever, the Varshavsky group next found Ac/N-degrons to be
conditional. They showed that participation in a protein
complex might sterically shield an Ac/N-degron from being
recognized by Ac/N-recognins, and therefore increase the
half-life of the Nt-acetylated subunit. Thus, free subunits
may have a short half-life that can be prolonged upon
formation of an oligomeric complex [5].
In their recent paper in Science, Hwang and Varshavsky
further advanced the N-end rule by taking it to the physio-
logical level [6]. Here, the authors show that a regulator
of mammalian G-protein signaling, Rgs2, is subjected to
degradation by the Ac/N-end rule pathway through the
Ac/N-recognin Teb4, the mammalian orthologue of the
yeast Doa10. This study revealed that two Rgs2 N-termi-
nal mutants (ML-Rgs2 and MR-Rgs2) that are associated
with hypertension are present at lower steady-state levels
compared to wild-type Rgs2 (MQ-Rgs2). This is owing
to the more rapid proteasome-dependent degradation of
ML-Rgs2 and MR-Rgs2 by either the Ac/N-end rule path-
way or by both Ac/N-end and Arg/N-end branches of the
N-end rule pathway (Figure 1). The increased N-end rule
targeting of mutant Rgs2 proteins may stem, in part, from
the altered kinetics of their Nt-acetylation prior to their
destruction by the N-end rule pathway.
The current study [6] represents a rare case in which the
effect of an Nt-acetyl group in a protein is explained all the
way from the molecular level (Ac/N-end rule mediated
degradation affecting G-protein signaling), to the cellular
level (vascular smooth muscle cell contraction), and finally
to the physiological level (hypertension). It is noteworthy
Spotlight
Glossary
Hypertension: high blood pressure and major risk factor for cardiovascular
diseases.
N-terminal (Nt) acetylation: common protein modification (occurring on !80%
of proteins) that involves the conjugation of an acetyl group (-COCH3) to the N
terminus of a protein (Nt-acetylation occurs largely co-translationally).
N-terminal acetyltransferases (NATs): substrate-specific enzymes that catalyze
N-terminal acetylation.
N-end rule pathway: a ubiquitin/proteasome-dependent proteolytic system
that recognizes degradation signals (degrons) whose main determinant is a
destabilizing N-terminal residue. It consists of two distinguished branches, the
Ac/N-end rule and the Arg/N-end rule pathway. The Ac/N-end rule branch
targets proteins with specific residues that are N-terminally acetylated. The
Arg/N-end rule branch instead targets proteins with unacetylated, destabilizing
N-terminal residues.
N-degron: an N-terminal degradation signal recognized by the N-end rule
pathway. Ac/N-degrons specifically include an acetylated N-terminal residue
(e.g., Ac-Met, Ac-Ala, Ac-Ser, Ac-Thr, and sometimes Ac-Val and Ac-Cys). Arg/
N-degrons have Arg, Lys, His, Leu, Phe, Tyr, Trp, or Ile, or unacetylated Met
when followed by a non-Met hydrophobic residue (Met-F/N-degron).
N-recognin: a ubiquitin ligase that recognizes N-degrons.
Vasoconstriction: the constriction of blood vessels, which increases blood
pressure.
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that it was a decrease in Nt-acetylation that caused in-
creased degradation of ML-Rgs2, because it allowed it to be
targeted additionally by the Arg/N-end rule pathway.
Thus, the Nt-acetylated and unacetylated forms of the
same protein can be targeted by the ‘complementary’ Ac/
N-end rule and Arg/N-end rule pathways in mammalian
cells, in agreement with the analogous understanding
recently attained with yeast cells [6,7].
Interestingly, one of the mutations (ML-Rgs2) shifted
Rgs2 from being a NatB substrate to a NatC substrate.
NatB completely or nearly completely Nt-acetylates most
of its substrates, whereas NatC appears to be less effica-
cious [8]. This means that NatC allows for partial Nt-
acetylation, resulting in a dual pool of Nt-acetylated and
Nt-unacetylated molecules for a given protein. The com-
plementarity of the Ac/N-end rule and Arg/N-end rule
branches of the N-end rule pathway makes it possible,
at least in some cases, to have distinct half-life regulations
of such pools. Hence, this recent study [6] suggests that the
level of Nt-acetylation of a given intracellular protein is a
significant parameter in its homeostasis.
The complementarity of the two N-end rule pathways
should be taken into consideration in studies performed
in the absence of NATs; for example, some earlier studies
of substrate subcellular localization [2]. The NAT sub-
strates under investigation may shift from Ac/N-end
to Arg/N-end rule mediated degradation, thus it should
be clarified whether the lack of Nt-acetylation causes
loss of membrane localization, or increased degradation,
or both. It would also be interesting to determine
whether the association of a protein with specific mem-
branes might sterically shield its N-degron, analogous
to the shielding of N-degrons within protein complexes
[5–7].
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Figure 1. N-terminal acetylation and the N-end rule pathway regulate Gq signaling and thereby hypertension. Regulator of G-protein signaling 2 (Rgs2, green), is a key
protein in the regulation of blood pressure through its inhibition of Gq protein signaling, which increases vasoconstriction and hence blood pressure. In healthy individuals
(left), wild-type Rgs2 (MQ-Rgs2) is subjected to N-terminal acetylation by the NatB Nt-acetyltransferase (purple), followed by degradation via the Ac/N-end rule pathway.
The ML-Rgs2 mutant is associated with hypertension in human patients (right). Although this mutant cannot be Nt-acetylated by NatB (in contrast to wild-type MQ-Rgs2), it
can be Nt-acetylated by NatC (orange). This change is likely to result in, among other things, a partial Nt-acetylation of ML-Rgs2. The pool of unacetylated ML-Rgs2
molecules is targeted by the Arg/N-end rule pathway, which recognizes the unacetylated Met residue if another hydrophobic residue follows it [7]. The pool of Nt-acetylated
ML-Rgs2 is targeted by the Ac/N-end rule pathway, similar to wild-type MQ-Rgs2. This dual degradation of mutant ML-Rgs2 by two different branches of the N-end rule
pathway strongly downregulates ML-Rgs2 and thereby increases the activity of G-protein signaling pathways that are normally repressed by Rgs2, resulting in excessive
vasoconstriction. The levels of another hypertension-associated variant, MR-Rgs2 (not shown), were also found to be lower than those of wild-type MQ-Rgs2, in the order
MQ > MR > ML [6]. MR-Rgs2 was analyzed less extensively and the reasons for its decreased cellular levels remain to be fully understood. Nevertheless, the decreased
cellular levels of both ML-Rgs2 and MR-Rgs2 are likely to account for the hypertension phenotypes conferred by these mutations in human Rgs2.
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of tropical forests has also been documented
elsewhere at this time (34–36). However, despite
potential fluctuations in the extent and produc-
tivity of Sri Lankan tropical forests associated
with these climatic changes, latePleistocenehuman
foragers maintained a reliance on intermediate
rainforest and tropical forest fringes. Therefore,
rainforests in South Asia have clearly long pro-
vided diverse and stable resources relied upon by
humans for at least the past 20,000 years.
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PROTEIN STABILITY
Control of mammalian G protein
signaling by N-terminal acetylation
and the N-end rule pathway
Sang-Eun Park,1* Jeong-Mok Kim,1* Ok-Hee Seok,1 Hanna Cho,1 Brandon Wadas,2
Seon-Young Kim,3,4 Alexander Varshavsky,2† Cheol-Sang Hwang1†
Rgs2, a regulator of G proteins, lowers blood pressure by decreasing signaling
through Gaq. Human patients expressing Met-Leu-Rgs2 (ML-Rgs2) or
Met-Arg-Rgs2 (MR-Rgs2) are hypertensive relative to people expressing wild-type
Met-Gln-Rgs2 (MQ-Rgs2). We found that wild-type MQ-Rgs2 and its mutant,
MR-Rgs2, were destroyed by the Ac/N-end rule pathway, which recognizes
Na-terminally acetylated (Nt-acetylated) proteins. The shortest-lived mutant,
ML-Rgs2, was targeted by both the Ac/N-end rule and Arg/N-end rule pathways.
The latter pathway recognizes unacetylated N-terminal residues. Thus,
the Nt-acetylated Ac-MX-Rgs2 (X = Arg, Gln, Leu) proteins are specific substrates
of the mammalian Ac/N-end rule pathway. Furthermore, the Ac/N-degron of
Ac-MQ-Rgs2 was conditional, and Teb4, an endoplasmic reticulum (ER) membrane-
embedded ubiquitin ligase, was able to regulate G protein signaling by targeting
Ac-MX-Rgs2 proteins for degradation through their Na-terminal acetyl group.
R
egulators of G protein signaling (RGSs)
bind to specific Ga subunits of heterotri-
meric G proteins (Gabg) and accelerate the
hydrolysis of Ga-bound guanosine tri-
phosphate, thereby abrogating the signal-
ing by G proteins (1–4). The mammalian Rgs2
protein regulates stress responses, translation,
circadian rhythms, Ca2+ channels, specific hor-
mones, and cardiovascular homeostasis (3–10).
Blood pressure–increasing vasoconstrictors such
as norepinephrine and angiotensin II are up-
regulated by activated Gaq proteins, which are
deactivated by Rgs2 (7). Both Rgs2−/− and het-
erozygous Rgs2+/− mice are strongly hyperten-
sive (8, 9). Human patients with decreased Rgs2
signaling are hypertensive as well (10).
In some hypertensive patients, one of two
Rgs2 genes encodes Met-Leu-Rgs2 (ML-Rgs2),
in which Gln at position 2 of wild-type Met-
Gln-Rgs2 (MQ-Rgs2) is replaced by Leu. An-
other hypertension-associated Rgs2 mutant is
Met-Arg-Rgs2 (MR-Rgs2) (10). The Gln→ Leu
and Gln → Arg mutations are not detected in
the general population (10). All three Rgs2 pro-
teins are up-regulated by a proteasome inhib-
itor, which suggests that they may be targeted
by a proteasome-dependent proteolytic sys-
tem (11).
The N-end rule pathway recognizes proteins
containing N-terminal (Nt) degradation signals
called N-degrons, polyubiquitylates these pro-
teins, and thereby causes their degradation by
the proteasome (fig. S1) (12–20). The main deter-
minant of an N-degron is a destabilizing Nt res-
idue of a protein. Recognition components of the
N-end rule pathway, called N-recognins, are E3
ubiquitin ligases that can target N-degrons. Reg-
ulated degradation of proteins by the N-end rule
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pathway mediates a broad range of biological
functions (fig. S1) (12–20).
TheN-end rulepathwayconsists of twobranches.
One branch, the Arg/N-end rule pathway, targets
unacetylated destabilizing Nt residues (12, 14, 16).
The Nt residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile, as well as Nt-Met [if it is followed by a
bulkyhydrophobic (Ф) residue], are directly recog-
nized by N-recognins (16). In contrast, the unacet-
ylatedAsn, Gln, Asp, andGlu (aswell as Cys, under
some conditions) Nt residues are destabilizing,
owing to their preliminary enzymatic modifica-
tions (fig. S1D).
The pathway’s other branch, called the Ac/N-
end rule pathway, targets proteins through their
Na-terminally acetylated (Nt-acetylated) residues
(fig. S1, A and C) (13, 15, 16). Degrons and E3
ubiquitin ligases of the Ac/N-end rule pathway
are called Ac/N-degrons and Ac/N-recognins,
respectively. Approximately 90% of human pro-
teins are cotranslationally and irreversibly Nt-
acetylated by ribosome-associated Nt-acetylases
(21, 22). (In contrast, acetylation of internal Lys
residues is reversible and largely posttranslational.)
Doa10, an ER membrane-embedded E3 ubiqui-
tin ligase of the yeast Saccharomyces cerevisiae
(23, 24), functions as anAc/N-recognin (13). Not4,
a cytosolic and nuclear E3, is another yeast Ac/N-
recognin (15).
The Arg/N-end rule pathway is present in all
examined eukaryotes, from fungi to mammals
and plants (fig. S1D) (12, 18, 19). In contrast, the
Ac/N-end rule pathway (fig. S1C) has been iden-
tified in S. cerevisiae (13, 15, 16), but its presence
in mammals and other multicellular eukaryotes
has been conjectural so far.
We began by subjecting wild-type humanMQ-
Rgs2 and its ML-Rgs2 mutant to cycloheximide
(CHX) chases in yeast (13, 15, 16). TheC-terminally
HA (hemagglutinin)–taggedMQ-Rgs2hawas short-
lived (t1/2 ≈ 30 min) in wild-type yeast and was
stabilized in bothnaa20D and doa10D cells, which
lacked, respectively, the cognateNatBNt-acetylase
and the Doa10 Ac/N-recognin (13) (Fig. 1, A and
C, and figs. S1C and S2). Thus, in yeast, wild-type
MQ-Rgs2hawas degraded largely by theAc/N-end
rule pathway (13, 15, 16).
Themutant humanML-Rgs2ha was also short-
lived in wild-type S. cerevisiae (t1/2 < 15 min) and
was partially stabilized in both naa30D andubr1D
cells, which lacked, respectively, the cognate NatC
Nt-acetylase and theUbr1N-recognin of theArg/N-
end rule pathway (Fig. 1, B and D, and figs. S1C,
S2, and S3, A and D). ML-Rgs2ha was nearly com-
pletely stabilized in double-mutant naa30D ubr1D
cells, including strongly elevated time-zero (pre-
chase) levels of ML-Rgs2ha (Fig. 1, B and D, and
fig. S3, A and D).
Many cellular proteins arepartiallyNt-acetylated
(21). Non–Nt-acetylated yeast MФ-type proteins
are eliminated by the Arg/N-end rule pathway,
whereas the Nt-acetylated counterparts of these
proteins are destroyed by the Ac/N-end rule path-
way (15, 16). This dual-targeting pattern was also
observedwith humanML-Rgs2ha (Fig. 1, B andD,
and fig. S3, A and D). The contribution of the
Ubr1N-recognin to the degradation ofML-Rgs2ha
(Fig. 1B and fig. S3A) indicated its incomplete Nt-
acetylation in S. cerevisiae, similarly to results
with naturalMФ-type yeast proteins (15, 16). Both
wild-typeMQ-Rgs2 and the second hypertension-
associated mutant MR-Rgs2 were targeted (after
their Nt-acetylation) solely by the Ac/N-end rule
pathway, because theunacetylatedNt-Met followed
by a non-Ф residue such as Gln or Arg is not rec-
ognized by the Arg/N-end rule pathway (in con-
trast to an MФ-type protein such as ML-Rgs2ha)
(fig. S1D) (16).
Wild-type MQ-Rgs2 is a predicted substrate
of the NatB Nt-acetylase (fig. S2), in agreement
with stabilization of MQ-Rgs2ha in naa20D
S. cerevisiae, which lack NatB (Fig. 1, A and C).
Using mass spectrometry (13), we analyzed the
MQ-Rgs2 protein from human embryonic kidney
(HEK) 293 cells, confirming its Nt-acetylation
(fig. S5A).
Considerably unequal levels of transiently ex-
pressed MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha
in human HeLa cells suggested their different
stabilities (MQ > MR > ML) in these cells—an
interpretation consistent with near-equal lev-
els of the correspondingMX-Rgs2 mRNAs (fig.
S4, C, F, and G). Indeed, CHX chases in HeLa
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Fig. 1. Rgs2 as an N-end rule substrate. (A) CHX chases with wild-type human MQ-Rgs2ha in wild-
type, naa20D, and doa10D S. cerevisiae. (B) As in (A) but with ML-Rgs2ha in wild-type, naa30D, ubr1D,
and naa30D ubr1D strains. (C to E) Quantification of data in (A), (B), and (F), respectively. See the
legend to fig. S3 for definitions of “100%” levels at zero time. (F) CHX chases with exogenously
expressed MX-Rgs2ha (X = Arg, Gln, Leu) in HeLa cells. (G) As in (F) but with MQ-Rgs2ha versus PQ-
Rgs2ha. (H) Quantification of data in (G). (I) CHX chases with exogenously expressed MR-Rgs2 in HeLa
cells subjected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse chases with MX-
Rgs2ha (X = Arg, Gln, Leu) in HeLa cells.
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pathway mediates a broad range of biological
functions (fig. S1) (12–20).
TheN-end rulepathwayconsists of twobranches.
One branch, the Arg/N-end rule pathway, targets
unacetylated destabilizing Nt residues (12, 14, 16).
The Nt residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile, as well as Nt-Met [if it is followed by a
bulkyhydrophobic (Ф) residue], are directly recog-
nized by N-recognins (16). In contrast, the unacet-
ylatedAsn, Gln, Asp, andGlu (aswell as Cys, under
some conditions) Nt residues are destabilizing,
owing to their preliminary enzymatic modifica-
tions (fig. S1D).
The pathway’s other branch, called the Ac/N-
end rule pathway, targets proteins through their
Na-terminally acetylated (Nt-acetylated) residues
(fig. S1, A and C) (13, 15, 16). Degrons and E3
ubiquitin ligases of the Ac/N-end rule pathway
are called Ac/N-degrons and Ac/N-recognins,
respectively. Approximately 90% of human pro-
teins are cotranslationally and irreversibly Nt-
acetylated by ribosome-associated Nt-acetylases
(21, 22). (In contrast, acetylation of internal Lys
residues is reversible and largely posttranslational.)
Doa10, an ER membrane-embedded E3 ubiqui-
tin ligase of the yeast Saccharomyces cerevisiae
(23, 24), functions as anAc/N-recognin (13). Not4,
a cytosolic and nuclear E3, is another yeast Ac/N-
recognin (15).
The Arg/N-end rule pathway is present in all
examined eukaryotes, from fungi to mammals
and plants (fig. S1D) (12, 18, 19). In contrast, the
Ac/N-end rule pathway (fig. S1C) has been iden-
tified in S. cerevisiae (13, 15, 16), but its presence
in mammals and other multicellular eukaryotes
has been conjectural so far.
We began by subjecting wild-type humanMQ-
Rgs2 and its ML-Rgs2 mutant to cycloheximide
(CHX) chases in yeast (13, 15, 16). TheC-terminally
HA (hemagglutinin)–taggedMQ-Rgs2hawas short-
lived (t1/2 ≈ 30 min) in wild-type yeast and was
stabilized in bothnaa20D and doa10D cells, which
lacked, respectively, the cognateNatBNt-acetylase
and the Doa10 Ac/N-recognin (13) (Fig. 1, A and
C, and figs. S1C and S2). Thus, in yeast, wild-type
MQ-Rgs2hawas degraded largely by theAc/N-end
rule pathway (13, 15, 16).
Themutant humanML-Rgs2ha was also short-
lived in wild-type S. cerevisiae (t1/2 < 15 min) and
was partially stabilized in both naa30D andubr1D
cells, which lacked, respectively, the cognate NatC
Nt-acetylase and theUbr1N-recognin of theArg/N-
end rule pathway (Fig. 1, B and D, and figs. S1C,
S2, and S3, A and D). ML-Rgs2ha was nearly com-
pletely stabilized in double-mutant naa30D ubr1D
cells, including strongly elevated time-zero (pre-
chase) levels of ML-Rgs2ha (Fig. 1, B and D, and
fig. S3, A and D).
Many cellular proteins arepartiallyNt-acetylated
(21). Non–Nt-acetylated yeast MФ-type proteins
are eliminated by the Arg/N-end rule pathway,
whereas the Nt-acetylated counterparts of these
proteins are destroyed by the Ac/N-end rule path-
way (15, 16). This dual-targeting pattern was also
observedwith humanML-Rgs2ha (Fig. 1, B andD,
and fig. S3, A and D). The contribution of the
Ubr1N-recognin to the degradation ofML-Rgs2ha
(Fig. 1B and fig. S3A) indicated its incomplete Nt-
acetylation in S. cerevisiae, similarly to results
with naturalMФ-type yeast proteins (15, 16). Both
wild-typeMQ-Rgs2 and the second hypertension-
associated mutant MR-Rgs2 were targeted (after
their Nt-acetylation) solely by the Ac/N-end rule
pathway, because theunacetylatedNt-Met followed
by a non-Ф residue such as Gln or Arg is not rec-
ognized by the Arg/N-end rule pathway (in con-
trast to an MФ-type protein such as ML-Rgs2ha)
(fig. S1D) (16).
Wild-type MQ-Rgs2 is a predicted substrate
of the NatB Nt-acetylase (fig. S2), in agreement
with stabilization of MQ-Rgs2ha in naa20D
S. cerevisiae, which lack NatB (Fig. 1, A and C).
Using mass spectrometry (13), we analyzed the
MQ-Rgs2 protein from human embryonic kidney
(HEK) 293 cells, confirming its Nt-acetylation
(fig. S5A).
Considerably unequal levels of transiently ex-
pressed MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha
in human HeLa cells suggested their different
stabilities (MQ > MR > ML) in these cells—an
interpretation consistent with near-equal lev-
els of the correspondingMX-Rgs2 mRNAs (fig.
S4, C, F, and G). Indeed, CHX chases in HeLa
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Fig. 1. Rgs2 as an N-end rule substrate. (A) CHX chases with wild-type human MQ-Rgs2ha in wild-
type, naa20D, and doa10D S. cerevisiae. (B) As in (A) but with ML-Rgs2ha in wild-type, naa30D, ubr1D,
and naa30D ubr1D strains. (C to E) Quantification of data in (A), (B), and (F), respectively. See the
legend to fig. S3 for definitions of “100%” levels at zero time. (F) CHX chases with exogenously
expressed MX-Rgs2ha (X = Arg, Gln, Leu) in HeLa cells. (G) As in (F) but with MQ-Rgs2ha versus PQ-
Rgs2ha. (H) Quantification of data in (G). (I) CHX chases with exogenously expressed MR-Rgs2 in HeLa
cells subjected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse chases with MX-
Rgs2ha (X = Arg, Gln, Leu) in HeLa cells.
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pathway mediates a broad range of biological
functions (fig. S1) (12–20).
TheN-end rulepathwayconsists of twobranches.
One branch, the Arg/N-end rule pathway, targets
unacetylated destabilizing Nt residues (12, 14, 16).
The Nt residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile, as well as Nt-Met [if it is followed by a
bulkyhydrophobic (Ф) residue], are directly recog-
nized by N-recognins (16). In contrast, the unacet-
ylatedAsn, Gln, Asp, andGlu (aswell as Cys, under
some conditions) Nt residues are destabilizing,
owing to their preliminary enzymatic modifica-
tions (fig. S1D).
The pathway’s other branch, called the Ac/N-
end rule pathway, targets proteins through their
Na-terminally acetylated (Nt-acetylated) residues
(fig. S1, A and C) (13, 15, 16). Degrons and E3
ubiquitin ligases of the Ac/N-end rule pathway
are called Ac/N-degrons and Ac/N-recognins,
respectively. Approximately 90% of human pro-
teins are cotranslationally and irreversibly Nt-
acetylated by ribosome-associated Nt-acetylases
(21, 22). (In contrast, acetylation of internal Lys
residues is reversible and largely posttranslational.)
Doa10, an ER membrane-embedded E3 ubiqui-
tin ligase of the yeast Saccharomyces cerevisiae
(23, 24), functions as anAc/N-recognin (13). Not4,
a cytosolic and nuclear E3, is another yeast Ac/N-
recognin (15).
The Arg/N-end rule pathway is present in all
examined eukaryotes, from fungi to mammals
and plants (fig. S1D) (12, 18, 19). In contrast, the
Ac/N-end rule pathway (fig. S1C) has been iden-
tified in S. cerevisiae (13, 15, 16), but its presence
in mammals and other multicellular eukaryotes
has been conjectural so far.
We began by subjecting wild-type humanMQ-
Rgs2 and its ML-Rgs2 mutant to cycloheximide
(CHX) chases in yeast (13, 15, 16). TheC-terminally
HA (hemagglutinin)–taggedMQ-Rgs2hawas short-
lived (t1/2 ≈ 30 min) in wild-type yeast and was
stabilized in bothnaa20D and doa10D cells, which
lacked, respectively, the cognateNatBNt-acetylase
and the Doa10 Ac/N-recognin (13) (Fig. 1, A and
C, and figs. S1C and S2). Thus, in yeast, wild-type
MQ-Rgs2hawas degraded largely by theAc/N-end
rule pathway (13, 15, 16).
Themutant humanML-Rgs2ha was also short-
lived in wild-type S. cerevisiae (t1/2 < 15 min) and
was partially stabilized in both naa30D andubr1D
cells, which lacked, respectively, the cognate NatC
Nt-acetylase and theUbr1N-recognin of theArg/N-
end rule pathway (Fig. 1, B and D, and figs. S1C,
S2, and S3, A and D). ML-Rgs2ha was nearly com-
pletely stabilized in double-mutant naa30D ubr1D
cells, including strongly elevated time-zero (pre-
chase) levels of ML-Rgs2ha (Fig. 1, B and D, and
fig. S3, A and D).
Many cellular proteins arepartiallyNt-acetylated
(21). Non–Nt-acetylated yeast MФ-type proteins
are eliminated by the Arg/N-end rule pathway,
whereas the Nt-acetylated counterparts of these
proteins are destroyed by the Ac/N-end rule path-
way (15, 16). This dual-targeting pattern was also
observedwith humanML-Rgs2ha (Fig. 1, B andD,
and fig. S3, A and D). The contribution of the
Ubr1N-recognin to the degradation ofML-Rgs2ha
(Fig. 1B and fig. S3A) indicated its incomplete Nt-
acetylation in S. cerevisiae, similarly to results
with naturalMФ-type yeast proteins (15, 16). Both
wild-typeMQ-Rgs2 and the second hypertension-
associated mutant MR-Rgs2 were targeted (after
their Nt-acetylation) solely by the Ac/N-end rule
pathway, because theunacetylatedNt-Met followed
by a non-Ф residue such as Gln or Arg is not rec-
ognized by the Arg/N-end rule pathway (in con-
trast to an MФ-type protein such as ML-Rgs2ha)
(fig. S1D) (16).
Wild-type MQ-Rgs2 is a predicted substrate
of the NatB Nt-acetylase (fig. S2), in agreement
with stabilization of MQ-Rgs2ha in naa20D
S. cerevisiae, which lack NatB (Fig. 1, A and C).
Using mass spectrometry (13), we analyzed the
MQ-Rgs2 protein from human embryonic kidney
(HEK) 293 cells, confirming its Nt-acetylation
(fig. S5A).
Considerably unequal levels of transiently ex-
pressed MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha
in human HeLa cells suggested their different
stabilities (MQ > MR > ML) in these cells—an
interpretation consistent with near-equal lev-
els of the correspondingMX-Rgs2 mRNAs (fig.
S4, C, F, and G). Indeed, CHX chases in HeLa
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Fig. 1. Rgs2 as an N-end rule substrate. (A) CHX chases with wild-type human MQ-Rgs2ha in wild-
type, naa20D, and doa10D S. cerevisiae. (B) As in (A) but with ML-Rgs2ha in wild-type, naa30D, ubr1D,
and naa30D ubr1D strains. (C to E) Quantification of data in (A), (B), and (F), respectively. See the
legend to fig. S3 for definitions of “100%” levels at zero time. (F) CHX chases with exogenously
expressed MX-Rgs2ha (X = Arg, Gln, Leu) in HeLa cells. (G) As in (F) but with MQ-Rgs2ha versus PQ-
Rgs2ha. (H) Quantification of data in (G). (I) CHX chases with exogenously expressed MR-Rgs2 in HeLa
cells subjected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse chases with MX-
Rgs2ha (X = Arg, Gln, Leu) in HeLa cells.
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pathway mediates a broad range of biological
functions (fig. S1) (12–20).
TheN-end rulepathwayconsists of twobranches.
One branch, the Arg/N-end rule pathway, targets
unacetylated destabilizing Nt residues (12, 14, 16).
The Nt residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile, as well as Nt-Met [if it is followed by a
bulkyhydrophobic (Ф) residue], are directly recog-
nized by N-recognins (16). In contrast, the unacet-
ylatedAsn, Gln, Asp, andGlu (aswell as Cys, under
some conditions) Nt residues are destabilizing,
owing to their preliminary enzymatic modifica-
tions (fig. S1D).
The pathway’s other branch, called the Ac/N-
end rule pathway, targets proteins through their
Na-terminally acetylated (Nt-acetylated) residues
(fig. S1, A and C) (13, 15, 16). Degrons and E3
ubiquitin ligases of the Ac/N-end rule pathway
are called c/N-degrons and Ac/N-recognins,
respectively. Approxim tely 90% of human pro-
t ins are cot anslation lly and irreversibly Nt-
acetylated by ribo ome-associated Nt-acety ase
(21, 22). (In contrast, acetylation of internal Lys
residues is reversible and largely posttranslational.)
Doa10, an ER m mbrane-embedded E3 ub qui-
tin ligase of the yeast Saccharomyces cerevisiae
(23, 24), functions as anAc/N-recognin (13). Not4,
a cytosolic and nuclear E3, is another yeast Ac/N-
recognin (15).
The Arg/N-end rule pathway is present in all
examined eukaryotes, from fungi to mammals
and plants (fig. S1D) (12, 18, 19). In contrast, the
Ac/N-end rule pathway (fig. S1C) has been iden-
tified in S. cerevisiae (13, 15, 16), but its presence
in mammals and other multicellular eukaryotes
has been conjectural so far.
We began by subjecting wild-type humanMQ-
Rgs2 and its ML-Rgs2 mutant to cycloheximide
(CHX) chases in yeast (13, 15, 16). TheC-terminally
HA (hemagglutinin)–taggedMQ-Rgs2hawas short-
lived (t1/2 ≈ 30 min) in wild-type yeast and was
stabilized in bothnaa20D and doa10D cells, which
lacked, respectively, the cognateNatBNt-acetylase
and the Doa10 Ac/N-recognin (13) (Fig. 1, A and
C, and figs. S1C and S2). Thus, in yeast, wild-type
MQ-Rgs2hawas degraded largely by theAc/N-end
rule pathway (13, 15, 16).
Themutant humanML-Rgs2ha was also short-
lived in wild-type S. cerevisiae (t1/2 < 15 min) and
was partially stabilized in both naa30D andubr1D
cells, which lacked, respectively, the cognate NatC
Nt-acetylase and theUbr1N-recognin of theArg/N-
end rule pathway (Fig. 1, B and D, and figs. S1C,
S2, and S3, A and D). L-Rgs2ha was nearly co -
pletely stabilized in double- utant naa30D ubr1D
cells, including strongly elevated ti e-zero (pre-
chase) levels of ML-Rgs2ha (Fig. 1, ,
fig. S3, A and D).
Many cellular proteins areparti ll
(21). Non–Nt-acetylated yeast -t
are eliminated by the Arg/ -e l
whereas the Nt-acetylated co t r
proteins are destroyed by the c/ -
way (15, 16). This dual-targeti g tt
observedwith human L-Rgs2ha ( i . , ,
and fig. S3, A and D). The co tri ti f t
Ubr1N-recognin to the degradatio of - gs2ha
(Fig. 1B and fig. S3A) indicated its incomplete Nt-
acetylation in S. cerevisiae, similarly to results
with naturalMФ-type yeast proteins (15, 16). Both
wild-typeMQ-Rgs2 and the second hypertension-
associated mutant MR-Rgs2 were targeted (after
their Nt-acetylation) solely by the Ac/N-end rule
pathway, because theunacetylatedNt-Met followed
by a non-Ф residue such as Gln or Arg is not rec-
ognized by the Arg/N-end rule pathway (in con-
trast to an MФ-type protein such as ML-Rgs2ha)
(fig. S1D) (16).
Wild-type MQ-Rgs2 is a predicted substrate
of the NatB Nt-acetylase (fig. S2), in agreement
with stabilization of MQ-Rgs2ha in naa20D
S. cerevisiae, which lack NatB (Fig. 1, A and C).
Using mass spectrometry (13), we analyzed the
MQ-Rgs2 protein from human embryonic kidney
(HEK) 293 cells, confirming its Nt-acetylation
(fig. S5A).
Considerably unequal levels of transiently ex-
pressed MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha
in human HeLa cells suggested their different
stabilities (MQ > MR > ML) in these cells—an
interpretation consistent with near-equal lev-
els of the correspondingMX-Rgs2 mRNAs (fig.
S4, C, F, and G). Indeed, CHX chases in HeLa
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i . . s2 as an N-end rule substrate. (A) CHX chases with wild-type human MQ-Rgs2ha in wild-
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ll jected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse chases with MX-
gs ha ( = Arg, Gln, Leu) in HeLa cells.
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pathway mediates a broad range of biological
functions (fig. S1) (12–20).
TheN-end rulepathwayconsists of twobranches.
One branch, the Arg/N-end rule pathway, targets
unacetylated destabilizing Nt residues (12, 14, 16).
The Nt residues Arg, Lys, His, Leu, Phe, Tyr, Trp,
and Ile, as well as Nt-Met [if it is followed by a
bulkyhydrophobic (Ф) residue], are directly recog-
nized by N-recognins (16). In contrast, the unacet-
ylatedAsn, Gln, Asp, andGlu (aswell as Cys, under
some conditions) Nt residues are destabilizing,
owing to their preliminary enzymatic modifica-
tions (fig. S1D).
The pathway’s other branch, called the Ac/N-
end rule pathway, targets proteins through their
Na-terminally acetylated (Nt-acetylated) residues
(fig. S1, A and C) (13, 15, 16). Degrons and E3
ubiquitin ligases of the Ac/N-end rule pathway
are called Ac/N-degrons and Ac/N-recognins,
respectively. Approximately 90% of human pro-
teins are cotranslationally and irreversibly Nt-
acetylated by ribosome-associated Nt-acetylases
(21, 22). (In contrast, acetylation of internal Lys
residues is reversible and largely posttranslational.)
Doa10, an ER membrane-embedded E3 ubiqui-
tin ligase of the yeast Saccharomyces cerevisiae
(23, 24), functions as anAc/N-recognin (13). Not4,
a cytosolic and nuclear E3, is another yeast Ac/N-
recognin (15).
The Arg/N-end rule pathway is present in all
examined eukaryotes, from fungi to mammals
and plants (fig. S1D) (12, 18, 19). In contrast, the
Ac/N-end rule pathway (fig. S1C) has been iden-
tified in S. cerevisiae (13, 15, 16), but its presence
in mammals and other multicellular eukaryotes
has been conjectural so far.
We began by subjecting wild-type humanMQ-
Rgs2 and its ML-Rgs2 mutant to cycloheximide
(CHX) chases in yeast (13, 15, 16). TheC-terminally
HA (hemagglutinin)–taggedMQ-Rgs2hawas short-
lived (t1/2 ≈ 30 min) in wild-type yeast and was
stabilized in bothnaa20D and doa10D cells, which
lacked, respectively, the cognateNatBNt-acetylase
and the Doa10 Ac/N-recognin (13) (Fig. 1, A and
C, and figs. S1C and S2). Thus, in yeast, wild-type
MQ-Rgs2hawas degraded largely by theAc/N-end
rule pathway (13, 15, 16).
Themutant humanML-Rgs2ha was also short-
lived in wild-type S. cerevisiae (t1/2 < 15 min) and
was partially stabilized in both naa30D andubr1D
cells, which lacked, respectively, the cognate NatC
Nt-acetylase and theUbr1N-recognin of theArg/N-
end rule pathway (Fig. 1, B and D, and figs. S1C,
S2, and S3, A and D). ML-Rgs2ha was nearly com-
pletely stabilized in double-mutant naa30D ubr1D
cells, including strongly elevated time-zero (pre-
chase) levels of ML-Rgs2ha (Fig. 1, B and D, and
fig. S3, A and D).
Many cellular proteins arepartiallyNt-acetylated
(21). Non–Nt-acetylated yeast MФ-type proteins
are eliminated by the Arg/N-end rule pathway,
whereas the Nt-acetylated counterparts of these
proteins are destroyed by the Ac/N-end rule path-
way (15, 16). This dual-targeting pattern was also
observedwith humanML-Rgs2ha (Fig. 1, B andD,
and fig. S3, A and D). The contribution of the
Ubr1N-recognin to the degradation ofML-Rgs2ha
(Fig. 1B and fig. S3A) indicated its incomplete Nt-
acetylation in S. cerevisiae, similarly to results
with naturalMФ-type yeast proteins (15, 16). Both
wild-typeMQ-Rgs2 and the second hypertension-
associated mutant MR-Rgs2 were targeted (after
their Nt-acetylation) solely by the Ac/N-end rule
pathway, because theunacetylatedNt-Met followed
by a non-Ф residue such as Gln or Arg is not rec-
ognized by the Arg/N-end rule pathway (in con-
trast to an MФ-type protein such as ML-Rgs2ha)
(fig. S1D) (16).
Wild-type MQ-Rgs2 is a predicted substrate
of the NatB Nt-acetylase (fig. S2), in agreement
with stabilization of MQ-Rgs2ha in naa20D
S. cerevisiae, which lack NatB (Fig. 1, A and C).
Using mass spectrometry (13), we analyzed the
MQ-Rgs2 protein from human embryonic kidney
(HEK) 293 cells, confirming its Nt-acetylation
(fig. S5A).
Considerably unequal levels of transiently ex-
pressed MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha
in human HeLa cells suggested their different
stabilities (MQ > MR > ML) in these cells—an
interpretation consistent with near-equal lev-
els of the correspondingMX-Rgs2 mRNAs (fig.
S4, C, F, and G). Indeed, CHX chases in HeLa
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Fig. 1. Rgs2 as an N-end rule substrate. (A) CHX chases with wild-type human MQ-Rgs2ha in wild-
type, naa20D, and doa10D S. cerevisiae. (B) As in (A) but with ML-Rgs2ha in wild-type, naa30D, ubr1D,
and naa30D ubr1D strains. (C to E) Quantification of data in (A), (B), and (F), respectively. See the
legend to fig. S3 for definitions of “100%” levels at zero time. (F) CHX chases with exogenously
expressed MX-Rgs2ha (X = Arg, Gln, Leu) in HeLa cells. (G) As in (F) but with MQ-Rgs2ha versus PQ-
Rgs2ha. (H) Quantification of data in (G). (I) CHX chases with exogenously expressed MR-Rgs2 in HeLa
cells subjected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse chases with MX-
Rgs2ha (X = Arg, Gln, Leu) in HeLa cells.
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cells showed that MR-Rgs2ha (t1/2 < 8 min) and
ML-Rgs2ha (t1/2 < 5min) were shorter-lived than
the also unstable wild-type MQ-Rgs2ha (t1/2 ≈
15 min) (Fig. 1, E and F, and fig. S3, B and E).
The same (MQ>MR>ML) order of degradation
rates was observed in 35S pulse chases of MQ-
Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Fig. 1J and
fig. S4J).
In contrast to Nt-acetylatable (and therefore
short-lived) wild-type MQ-Rgs2ha, the other-
wise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha), gen-
erated cotranslationally from MPQ-Rgs2ha, was
neither Nt-acetylated nor recognized by the
Arg/N-end rule pathway (figs. S1 and S2). PQ-
Rgs2ha was long-lived in HeLa cells (Fig. 1, G and
H). This result was an additional, conceptually
independent piece of evidence for the targeting
of Ac-MQ-Rgs2ha by the Ac/N-end rule pathway
(fig. S1C).
Remarkably, the exogenous (overexpressed)
wild-type MQ-Rgs2ha was much shorter-lived
(t1/2 ≈ 15 min) than the endogenous MQ-Rgs2
(t1/2 ≈ 3 hours) in HeLa cells that did not over-
express MQ-Rgs2ha (Fig. 1, E and F, Fig. 2B, and
figs. S3, B and E, and S4, A and B). These results,
with human cells, agreed with the recent dem-
onstration of the biologically relevant condition-
ality of S. cerevisiae Ac/N-degrons (through their
steric shielding in cognate protein complexes)
(15). Given this understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present
results (fig. S4, A and B) are what one would
expect if Ac-MQ-Rgs2, in human cells that do
not overexpress it, can be (reversibly) shielded
from the Ac/N-end rule pathway soon after Nt-
acetylation of MQ-Rgs2. This shielding would
occur through formation of one or more phys-
iologically relevant protective complexes be-
tween Ac-MQ-Rgs2 and its protein ligand(s).
In contrast to the long half-life of the endog-
enous, “stoichiometrically” expressed MQ-Rgs2,
its overexpression in HeLa cells would make
the resulting “unprotectable” excess of Ac-MQ-
Rgs2ha molecules vulnerable to destruction by
the Ac/N-end rule pathway, thereby account-
ing for the large difference between the slowly
degraded endogenous MQ-Rgs2 (in cells that
do not overexpress MQ-Rgs2) and the short
half-life of overexpressed MQ-Rgs2ha (fig. S4, A
and B). Indeed, the short-lived MQ-Rgs2 was
strongly stabilized by co-overexpression of one
of its binding partners, the Gaq protein (Fig. 3,
A and B).
A candidate Ac/N-recognin of the mamma-
lian Ac/N-end rule pathway was Teb4, an ER
membrane–embedded E3 ubiquitin ligase that
polyubiquitylates proteins retrotranslocated from
the ER. Teb4 is similar to the S. cerevisiae Doa10
Ac/N-recognin (13, 23, 24).We found that human
Teb4 was indeed an Ac/N-recognin:
1) Transiently expressed MQ-Rgs2ha was up-
regulated by a proteasome inhibitor, where-
as coexpression of human Teb4 (Teb43f) and
MQ-Rgs2ha in HeLa cells down-regulated MQ-
Rgs2ha (Fig. 2, A and F). In addition, incre-
mentally higher levels of Teb43f resulted in
incrementally lower levels of endogenous MQ-
Rgs2 (Fig. 2G).
2) The level of MQ-Rgs2ha in HeLa cells was
not decreased whenMQ-Rgs2ha was coexpressed
with Teb4C9A3f , a missense mutant that is inactive
as a ubiquitin ligase (24) (Fig. 2F). Analogous as-
says with MR-Rgs2ha and ML-Rgs2ha gave similar
results (fig. S4, D and E).
3) The in vivo polyubiquitylation of MQ-
Rgs2ha in HeLa cells was increased by coexpres-
sion of Teb43f, but not by coexpression of the
mutant Teb4C9A3f (fig. S3F).
4) In CHX chases, endogenous MQ-Rgs2 was
stabilized by RNA interference (RNAi)–mediated
knockdowns of either endogenous Teb4 E3 or
endogenous cognate NatB Nt-acetylase (Fig. 2B
and fig. S4A). Similar results were obtained with
exogenous (overexpressed) MQ-Rgs2ha, confirm-
ing the targeting of MQ-Rgs2 by Teb4 and indi-
cating that this targeting required Nt-acetylation
of MQ-Rgs2 by the NatB Nt-acetylase (Fig. 2B
and fig. S4, A and B). In addition, overexpressed
(hypertension-associated) MR-Rgs2ha as well
as the engineered MK-Rgs2ha (which has a dif-
ferent basic residue at position 2) were stabil-
ized by RNAi-based knockdown of Naa60, the
catalytic subunit of cognate NatF Nt-acetylase
(21, 22), but these MX-Rgs2ha proteins were not
stabilized by knockdown of the noncognate
NatB (Naa20) Nt-acetylase (Fig. 1I and fig. S4,
H and I).
5) Cross-linking and coimmunoprecipitation
experiments indicated that Teb4 interacted with
MQ-Rgs2 (more accurately, with Nt-acetylated
Ac-MQ-Rgs2ha, as shown below) (Fig. 2, H and I).
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Fig. 2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without Teb43f or the MG132
proteasome inhibitor. (B) CHX chases with endogenous MQ-Rgs2, Teb4, and Naa20 subjected to RNAi
for a “scrambled” target, Teb4, or Naa20. The asterisk indicates a protein cross-reacting with anti-Teb4.
(C) Molecular weight standards, purified MQ-Rgs21-10-GST, and purified Ac-MQ-Rgs21-10-GST, respec-
tively. (D) Lane 1, Teb43f input; lanes 2 to 4, GST pull-downs with GST alone, MQ-Rgs21-10-GST, and Ac-
MQ-Rgs21-10-GST, respectively. (E) As in (D) but Coomassie-stained GST fusions released from beads.
(F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb4
C9A
3f . (G) Increases in Teb43f led
to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-Rgs2ha alone (lane 1) or together with
Teb43f (lane 2) were treated with a cell-penetrating cross-linker, followed by immunoprecipitations
with anti-FLAG, reversal of cross-links, SDS–polyacrylamide gel electrophoresis (PAGE), and immu-
noblotting with anti-HA and anti-FLAG. (I) As in (H) but Teb43f alone in lane 1, and immunoprecipi-
tations with anti-HA.
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cells showed that MR-Rgs2ha (t1/2 < 8 min) and
ML-Rgs2ha (t1/2 < 5min) were shorter-lived than
the also unstable wild-type MQ-Rgs2ha (t1/2 ≈
15 min) (Fig. 1, E and F, and fig. S3, B and E).
The same (MQ>MR>ML) order of degradation
rates was observed in 35S pulse chases of MQ-
Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Fig. 1J and
fig. S4J).
In contrast to Nt-acetylatable (and therefore
short-lived) wild-type MQ-Rgs2ha, the other-
wise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha), gen-
erated cotranslationally from MPQ-Rgs2ha, was
neither Nt-acetylated nor recognized by the
Arg/N-end rule pathway (figs. S1 and S2). PQ-
Rgs2ha was long-lived in HeLa cells (Fig. 1, G and
H). This result was an additional, conceptually
independent piece of evidence for the targeting
of Ac-MQ-Rgs2ha by the Ac/N-end rule pathway
(fig. S1C).
Remarkably, the exogenous (overexpressed)
wild-type MQ-Rgs2ha was much shorter-lived
(t1/2 ≈ 15 min) than the endogenous MQ-Rgs2
(t1/2 ≈ 3 hours) in HeLa cells that did not over-
express MQ-Rgs2ha (Fig. 1, E and F, Fig. 2B, and
figs. S3, B and E, and S4, A and B). These results,
with human cells, agreed with the recent dem-
onstration of the biologically relevant condition-
ality of S. cerevisiae Ac/N-degrons (through their
steric shielding in cognate protein complexes)
(15). Given this understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present
results (fig. S4, A and B) are what one would
expect if Ac-MQ-Rgs2, in human cells that do
not overexpress it, can be (reversibly) shielded
from the Ac/N-end rule pathway soon after Nt-
acetylation of MQ-Rgs2. This shielding would
occur through formation of one or more phys-
iologically relevant protective complexes be-
tween Ac-MQ-Rgs2 and its protein ligand(s).
In contrast to the long half-life of the endog-
enous, “stoichiometrically” expressed MQ-Rgs2,
its overexpression in HeLa cells would make
the resulting “unprotectable” excess of Ac-MQ-
Rgs2ha molecules vulnerable to destruction by
the Ac/N-end rule pathway, thereby account-
ing for the large difference between the slowly
degraded endogenous MQ-Rgs2 (in cells that
do not overexpress MQ-Rgs2) and the short
half-life of overexpressed MQ-Rgs2ha (fig. S4, A
and B). Indeed, the short-lived MQ-Rgs2 was
strongly stabilized by co-overexpression of one
of its binding partners, the Gaq protein (Fig. 3,
A and B).
A candidate Ac/N-recognin of the mamma-
lian Ac/N-end rule pathway was Teb4, an ER
membrane–embedded E3 ubiquitin ligase that
polyubiquitylates proteins retrotranslocated from
the ER. Teb4 is similar to the S. cerevisiae Doa10
Ac/N-recognin (13, 23, 24).We found that human
Teb4 was indeed an Ac/N-recognin:
1) Transiently expressed MQ-Rgs2ha was up-
regulated by a proteasome inhibitor, where-
as coexpression of human Teb4 (Teb43f) and
MQ-Rgs2ha in HeLa cells down-regulated MQ-
Rgs2ha (Fig. 2, A and F). In addition, incre-
mentally higher levels of Teb43f resulted in
incrementally lower levels of endogenous MQ-
Rgs2 (Fig. 2G).
2) The level of MQ-Rgs2ha in HeLa cells was
not decreased whenMQ-Rgs2ha was coexpressed
with Teb4C9A3f , a missense mutant that is inactive
as a ubiquitin ligase (24) (Fig. 2F). Analogous as-
says with MR-Rgs2ha and ML-Rgs2ha gave similar
results (fig. S4, D and E).
3) The in vivo polyubiquitylation of MQ-
Rgs2ha in HeLa cells was increased by coexpres-
sion of Teb43f, but not by coexpression of the
mutant Teb4C9A3f (fig. S3F).
4) In CHX chases, endogenous MQ-Rgs2 was
stabilized by RNA interference (RNAi)–mediated
knockdowns of either endogenous Teb4 E3 or
endogenous cognate NatB Nt-acetylase (Fig. 2B
and fig. S4A). Similar results were obtained with
exogenous (overexpressed) MQ-Rgs2ha, confirm-
ing the targeting of MQ-Rgs2 by Teb4 and indi-
cating that this targeting required Nt-acetylation
of MQ-Rgs2 by the NatB Nt-acetylase (Fig. 2B
and fig. S4, A and B). In addition, overexpressed
(hypertension-associated) MR-Rgs2ha as well
as the engineered MK-Rgs2ha (which has a dif-
ferent basic residue at position 2) were stabil-
ized by RNAi-based knockdown of Naa60, the
catalytic subunit of cognate NatF Nt-acetylase
(21, 22), but these MX-Rgs2ha proteins were not
stabilized by knockdown of the noncognate
NatB (Naa20) Nt-acetylase (Fig. 1I and fig. S4,
H and I).
5) Cross-linking and coimmunoprecipitation
experiments indicated that Teb4 interacted with
MQ-Rgs2 (more accurately, with Nt-acetylated
Ac-MQ-Rgs2ha, as shown below) (Fig. 2, H and I).
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Fig. 2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without Teb43f or the MG132
proteasome inhibitor. (B) CHX chases with endogenous MQ-Rgs2, Teb4, and Naa20 subjected to RNAi
for a “scrambled” target, Teb4, or Naa20. The asterisk indicates a protein cross-reacting with anti-Teb4.
(C) Molecular weight standards, purified MQ-Rgs21-10-GST, and purified Ac-MQ-Rgs21-10-GST, respec-
tively. (D) Lane 1, Teb43f input; lanes 2 to 4, GST pull-downs with GST alone, MQ-Rgs21-10-GST, and Ac-
MQ-Rgs21-10-GST, respectively. (E) As in (D) but Coomassie-stained GST fusions released from beads.
(F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb4
C9A
3f . (G) Increases in Teb43f led
to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-Rgs2ha alone (lane 1) or together with
Teb43f (lane 2) were treated with a cell-penetrating cross-linker, followed by immunoprecipitations
with anti-FLAG, reversal of cross-links, SDS–polyacrylamide gel electrophoresis (PAGE), and immu-
noblotting with anti-HA and anti-FLAG. (I) As in (H) but Teb43f alone in lane 1, and immunoprecipi-
tations with anti-HA.
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cells showed that MR-Rgs2ha (t1/2 < 8 min) and
ML-Rgs2ha (t1/2 < 5min) were shorter-lived than
the also unstable wild-type MQ-Rgs2ha (t1/2 ≈
15 min) (Fig. 1, E and F, and fig. S3, B and E).
The same (MQ>MR>ML) order of degradation
rates was observed in 35S pulse chases of MQ-
Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Fig. 1J and
fig. S4J).
In contrast to Nt-acetylatable (and therefore
short-lived) wild-type MQ-Rgs2ha, the other-
wise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha), gen-
erated cotranslationally from MPQ-Rgs2ha, was
neither Nt-acetylated nor recognized by the
Arg/N-end rule pathway (figs. S1 and S2). PQ-
Rgs2ha was long-lived in HeLa cells (Fig. 1, G and
H). This result was an additional, conceptually
independent piece of evidence for the targeting
of Ac-MQ-Rgs2ha by the Ac/N-end rule pathway
(fig. S1C).
Remarkably, the exogenous (overexpressed)
wild-type MQ-Rgs2ha was much shorter-lived
(t1/2 ≈ 15 min) than the endogenous MQ-Rgs2
(t1/2 ≈ 3 hours) in HeLa cells that did not over-
express MQ-Rgs2ha (Fig. 1, E and F, Fig. 2B, and
figs. S3, B and E, and S4, A and B). These results,
with human cells, agreed with the recent dem-
onstration of the biologically relevant condition-
ality of S. cerevisiae Ac/N-degrons (through their
steric shielding in cognate protein complexes)
(15). Given this understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present
results (fig. S4, A and B) are what one would
expect if Ac-MQ-Rgs2, in human cells that do
not overexpress it, can be (reversibly) shielded
from the Ac/N-end rule pathway soon after Nt-
acetylation of MQ-Rgs2. This shielding would
occur through formation of one or more phys-
iologically relevant protective complexes be-
tween Ac-MQ-Rgs2 and its protein ligand(s).
In contrast to the long half-life of the endog-
enous, “stoichiometrically” expressed MQ-Rgs2,
its overexpression in HeLa cells would make
the resulting “unprotectable” excess of Ac-MQ-
Rgs2ha molecules vulnerable to destruction by
the Ac/N-end rule pathway, thereby account-
ing for the large difference between the slowly
degraded endogenous MQ-Rgs2 (in cells that
do not overexpress MQ-Rgs2) and the short
half-life of overexpressed MQ-Rgs2ha (fig. S4, A
and B). Indeed, the short-lived MQ-Rgs2 was
strongly stabilized by co-overexpression of one
of its binding partners, the Gaq protein (Fig. 3,
A and B).
A candidate Ac/N-recognin of the mamma-
lian Ac/N-end rule pathway was Teb4, an ER
membrane–embedded E3 ubiquitin ligase that
polyubiquitylates proteins retrotranslocated from
the ER. Teb4 is similar to the S. cerevisiae Doa10
Ac/N-recognin (13, 23, 24).We found that human
Teb4 was indeed an Ac/N-recognin:
1) Transiently expressed MQ-Rgs2ha was up-
regulated by a proteasome inhibitor, where-
as coexpression of human Teb4 (Teb43f) and
MQ-Rgs2ha in HeLa cells down-regulated MQ-
Rgs2ha (Fig. 2, A and F). In addition, incre-
mentally higher levels of Teb43f resulted in
incrementally lower levels of endogenous MQ-
Rgs2 (Fig. 2G).
2) The level of MQ-Rgs2ha in HeLa cells was
not decreased whenMQ-Rgs2ha was coexpressed
with Teb4C9A3f , a missense mutant that is inactive
as a ubiquitin ligase (24) (Fig. 2F). Analogous as-
says with MR-Rgs2ha and ML-Rgs2ha gave similar
results (fig. S4, D and E).
3) The in vivo polyubiquitylation of MQ-
Rgs2ha in HeLa cells was increased by coexpres-
sion of Teb43f, but not by coexpression of the
mutant Teb4C9A3f (fig. S3F).
4) In CHX chases, endogenous MQ-Rgs2 was
stabilized by RNA interference (RNAi)–mediated
knockdowns of either endogenous Teb4 E3 or
endogenous cognate NatB Nt-acetylase (Fig. 2B
and fig. S4A). Similar results were obtained with
exogenous (overexpressed) MQ-Rgs2ha, confirm-
ing the targeting of MQ-Rgs2 by Teb4 and indi-
cating that this targeting required Nt-acetylation
of MQ-Rgs2 by the NatB Nt-acetylase (Fig. 2B
and fig. S4, A and B). In addition, overexpressed
(hypertension-associated) MR-Rgs2ha as well
as the engineered MK-Rgs2ha (which has a dif-
ferent basic residue at position 2) were stabil-
ized by RNAi-based knockdown of Naa60, the
catalytic subunit of cognate NatF Nt-acetylase
(21, 22), but these MX-Rgs2ha proteins were not
stabilized by knockdown of the noncognate
NatB (Naa20) Nt-acetylase (Fig. 1I and fig. S4,
H and I).
5) Cross-linking and coimmunoprecipitation
experiments indicated that Teb4 interacted with
MQ-Rgs2 (more accurately, with Nt-acetylated
Ac-MQ-Rgs2ha, as shown below) (Fig. 2, H and I).
SCIENCE sciencemag.org 13 MARCH 2015 • VOL 347 ISSUE 6227 1251
Fig. 2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without Teb43f or the MG132
proteasome inhibitor. (B) CHX chases with endogenous MQ-Rgs2, Teb4, and Naa20 subjected to RNAi
for a “scrambled” target, Teb4, or Naa20. The asterisk indicates a protein cross-reacting with anti-Teb4.
(C) Molecular weight standards, purified MQ-Rgs21-10-GST, and purified Ac-MQ-Rgs21-10-GST, respec-
tively. (D) Lane 1, Teb43f input; lanes 2 to 4, GST pull-downs with GST alone, MQ-Rgs21-10-GST, and Ac-
MQ-Rgs21-10-GST, respectively. (E) As in (D) but Coomassie-stained GST fusions released from beads.
(F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb4
C9A
3f . (G) Increases in Teb43f led
to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-Rgs2ha alone (lane 1) or together with
Teb43f (lane 2) were treated with a cell-penetrating cross-linker, followed by immunoprecipitations
with anti-FLAG, reversal of cross-links, SDS–polyacrylamide gel electrophoresis (PAGE), and immu-
noblotting with anti-HA and anti-FLAG. (I) As in (H) but Teb43f alone in lane 1, and immunoprecipi-
tations with anti-HA.
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cells showed that MR-Rgs2ha (t1/2 < 8 min) and
ML-Rgs2ha (t1/2 < 5min) were shorter-lived than
the also unstable wild-type MQ-Rgs2ha (t1/2 ≈
15 min) (Fig. 1, E and F, and fig. S3, B and E).
The same (MQ>MR>ML) order of degradation
rates was observed in 35S pulse chases of MQ-
Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Fig. 1J and
fig. S4J).
In contrast to Nt-acetylatable (and therefore
short-lived) wild-type MQ-Rgs2ha, the other-
wise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha), gen-
erated cotranslationally from MPQ-Rgs2ha, was
neither Nt-acetylated nor recognized by the
Arg/N-end rule pathway (figs. S1 and S2). PQ-
Rgs2ha was long-lived in HeLa cells (Fig. 1, G and
H). This result was an additional, conceptually
independent piece of evidence for the targeting
of Ac-MQ-Rgs2ha by the Ac/N-end rule pathway
(fig. S1C).
Remarkably, the exogenous (overexpressed)
wild-type MQ-Rgs2ha was much shorter-lived
(t1/2 ≈ 15 min) than the endogenous MQ-Rgs2
(t1/2 ≈ 3 hours) in HeLa cells that did not over-
express MQ-Rgs2ha (Fig. 1, E and F, Fig. 2B, and
figs. S3, B and E, and S4, A and B). These results,
with human cells, agreed with the recent dem-
onstration of the biologically relevant condition-
ality of S. cerevisiae Ac/N-degrons (through their
steric shielding in cognate protein complexes)
(15). Given this understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present
results (fig. S4, A and B) are what one would
expect if Ac-MQ-Rgs2, in human cells that do
not overexpress it, can be (reversibly) shielded
from the Ac/N-end rule pathway soon after Nt-
acetylation of MQ-Rgs2. This shielding would
occur through formation of one or more phys-
iologically relevant protective complexes be-
tween Ac-MQ-Rgs2 and its protein ligand(s).
In contrast to the long half-life of the endog-
enous, “stoichiometrically” expressed MQ-Rgs2,
its overexpression in HeLa cells would make
the resulting “unprotectable” excess of Ac-MQ-
Rgs2ha molecules vulnerable to destruction by
the Ac/N-end rule pathway, thereby account-
ing for the large difference between the slowly
degraded endogenous MQ-Rgs2 (in cells that
do not overexpress MQ-Rgs2) and the short
half-life of overexpressed MQ-Rgs2ha (fig. S4, A
and B). Indeed, the short-lived MQ-Rgs2 was
strongly stabilized by co-overexpression of one
of its binding partners, the Gaq protein (Fig. 3,
A and B).
A candidate Ac/N-recognin of the mamma-
lian Ac/N-end rule pathway was Teb4, an ER
membrane–embedded E3 ubiquitin ligase that
polyubiquitylates proteins retrotranslocated from
the ER. Teb4 is similar to the S. cerevisiae Doa10
Ac/N-recognin (13, 23, 24).We found that human
Teb4 was indeed an Ac/N-recognin:
1) Transiently expressed MQ-Rgs2ha was up-
regulated by a proteasome inhibitor, where-
as coexpression of human Teb4 (Teb43f) and
MQ-Rgs2ha in HeLa cells down-regulated MQ-
Rgs2ha (Fig. 2, A and F). In addition, incre-
mentally higher levels of Teb43f resulted in
incrementally lower levels of endogenous MQ-
Rgs2 (Fig. 2G).
2) The level of MQ-Rgs2ha in HeLa cells was
not decreased whenMQ-Rgs2ha was coexpressed
with Teb4C9A3f , a missense mutant that is inactive
as a ubiquitin ligase (24) (Fig. 2F). Analogous as-
says with MR-Rgs2ha and ML-Rgs2ha gave similar
results (fig. S4, D and E).
3) The in vivo polyubiquitylation of MQ-
Rgs2ha in HeLa cells was increased by coexpres-
sion of Teb43f, but not by coexpression of the
mutant Teb4C9A3f (fig. S3F).
4) In CHX chases, endogenous MQ-Rgs2 was
stabilized by RNA interference (RNAi)–mediated
knockdowns of either endogenous Teb4 E3 or
endogenous cognate NatB Nt-acetylase (Fig. 2B
and fig. S4A). Similar results were obtained with
exogenous (overexpressed) MQ-Rgs2ha, confirm-
ing the targeting of MQ-Rgs2 by Teb4 and indi-
cating that this targeting required Nt-acetylation
of MQ-Rgs2 by the NatB Nt-acetylase (Fig. 2B
and fig. S4, A and B). In addition, overexpressed
(hypertension-associated) MR-Rgs2ha as well
as the engineered MK-Rgs2ha (which has a dif-
ferent basic residue at position 2) were stabil-
ized by RNAi-based knockdown of Naa60, the
catalytic subunit of cognate NatF Nt-acetylase
(21, 22), but these MX-Rgs2ha proteins were not
stabilized by knockdown of the noncognate
NatB (Naa20) Nt-acetylase (Fig. 1I and fig. S4,
H and I).
5) Cross-linking and coimmunoprecipitation
experiments indicated that Teb4 interacted with
MQ-Rgs2 (more accurately, with Nt-acetylated
Ac-MQ-Rgs2ha, as shown below) (Fig. 2, H and I).
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Fig. 2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without Teb43f or the MG132
proteasome inhibitor. (B) CHX chases with endogenous MQ-Rgs2, Teb4, and Naa20 subjected to RNAi
for a “scrambled” target, Teb4, or Naa20. The asterisk indicates a protein cross-reacting with anti-Teb4.
(C) Molecular weight standards, purified MQ-Rgs21-10-GST, and purified Ac-MQ-Rgs21-10-GST, respec-
tively. (D) Lane 1, Teb43f input; lanes 2 to 4, GST pull-downs with GST alone, MQ-Rgs21-10-GST, and Ac-
MQ-Rgs21-10-GST, respectively. (E) As in (D) but Coomassie-stained GST fusions released from beads.
(F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb4
C9A
3f . (G) Increases in Teb43f led
to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-Rgs2ha alone (lane 1) or together with
Teb43f (lane 2) were treated with a cell-penetrating cross-linker, followed by immunoprecipitations
with anti-FLAG, reversal of cross-links, SDS–polyacrylamide gel electrophoresis (PAGE), and immu-
noblotting with anti-HA and anti-FLAG. (I) As in (H) but Teb43f alone in lane 1, and immunoprecipi-
tations with anti-HA.
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cells showed that MR-Rgs2ha (t1/2 < 8 min) and
ML-Rgs2ha (t1/2 < 5min) were shorter-lived than
the also unstable wild-type MQ-Rgs2ha (t1/2 ≈
15 min) (Fig. 1, E and F, and fig. S3, B and E).
The same (MQ>MR>ML) order of degradation
rates was observed in 35S pulse chases of MQ-
Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Fig. 1J and
fig. S4J).
In contrast to Nt-acetylatable (and therefore
short-lived) wild-type MQ-Rgs2ha, the other-
wise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha), gen-
erated cotran lationally from MPQ-Rgs2ha, was
neither Nt-acetylate or recognized by the
Arg/N-end rule pathway (figs. S1 and S2). PQ-
Rgs2ha was long-lived in HeLa cells (Fig. 1, G and
H). This result was an additional, conceptually
independent piece of evidence for the targeting
of Ac-MQ-Rgs2ha by the Ac/N-end rule pathway
(fig. S1C).
Remarkably, the exogenous (overexpressed)
wild-type MQ-Rgs2ha was much shorter-lived
(t1/2 ≈ 15 min) than the endogenous MQ-Rgs2
(t1/2 ≈ 3 hours) in HeLa cells that did not over-
express MQ-Rgs2ha (Fig. 1, E and F, Fig. 2B, and
figs. S3, B and E, and S4, A and B). These results,
with human cells, agreed with the recent dem-
onstration of the biologically relevant condition-
ality of S. cerevisiae Ac/N-degrons (thr ugh their
st ric shielding in cognate protein complexes)
(15). Given thi understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present
results (fig. S4, A and B) are what one would
expect if Ac-MQ-Rgs2, in human cells that do
not overexpress it, can be (reversibly) shielded
from the Ac/N-end rule pathway soon after Nt-
acetylation of MQ-Rgs2. This shielding would
occur through formation of one or more phys-
iologically relevant protective complexes be-
tween Ac-MQ-Rgs2 and its protein ligand(s).
In contrast to the long half-life of the endog-
enous, “stoichiometrically” expressed MQ-Rgs2,
its overexpression in HeLa cells would make
the resulting “unprotectable” excess of Ac-MQ-
Rgs2ha molecules vulnerable to destruction by
the Ac/N-end rule pathway, thereby account-
ing for the larg iffer nce betwe n the slowly
deg aded endogenous MQ-Rgs2 (in c lls that
do not overexpress MQ-Rgs2) and the short
half-life of overexpressed MQ-Rgs2ha (fig. S4, A
and B). Indeed, the short-lived MQ-Rgs2 was
strongly stabilized by co-overexpression of one
of its binding partners, the Gaq protein (Fig. 3,
A and B).
A candidate Ac/N-recognin of the mamma-
lian Ac/N-end rule pathway was Teb4, an ER
membrane–embedded E3 ubiquitin ligase that
polyubiquitylates proteins retrotranslocated from
the ER. Teb4 is similar to the S. cerevisiae Doa10
Ac/N-recognin (13, 23, 24).We found that human
Teb4 was indeed a Ac/N-recognin:
1) Transiently expressed MQ-Rgs2ha was up-
regulated by a proteasome inhibitor, where-
as coexpression of human Teb4 (Teb43f) and
MQ-Rgs2ha in HeLa cells down-regulated MQ-
Rgs2ha (Fig. 2, A and F). In addition, incre-
mentally higher levels of Teb43f resulted in
incrementally lower levels of endogenous MQ-
Rgs2 (Fig. 2G).
2) The level of MQ-Rgs2ha in HeLa cells was
not decreased whenMQ-Rgs2ha was coexpressed
with Teb4C9A3f , a missense mutant that is inactive
as a ubiquitin ligase (24) (Fig. 2F). Analogous as-
says with MR-Rgs2ha and ML-Rgs2ha gave similar
results (fig. S4, D nd E).
3) The in vivo polyubiquitylation of MQ-
Rgs2ha i HeLa cells was increased by coexpres-
sion of Teb43f, but not by coexpression of the
mutant Teb4C9A3f (fig. S3F).
4) In CHX chases, endogenous MQ-Rgs2 was
stabilized by RNA interference (RNAi)–mediated
knockdowns of either endogenous Teb4 E3 or
endogenous cognate NatB Nt-acetylase (Fig. 2B
and fig. S4A). Similar results were obtained with
exogenous (overexpressed) MQ-Rgs2ha, confirm-
ing the targeting of MQ-Rgs2 by Teb4 and indi-
cating that this targeting required Nt-acetylation
of MQ-Rgs2 by the NatB Nt-ace ylase (Fig. 2B
and fig. S4, A and B). In ddition, overexpressed
(hypert nsion-associated) MR-Rgs2ha as well
as the engineered MK-Rgs2ha (which has a dif-
ferent basic residue at position 2) were stabil-
ized by RNAi-based knockdown of Naa60, the
catalytic subunit of cognate NatF Nt-acetylase
(21, 22), but these MX-Rgs2ha proteins were not
stabilized by knockdown of the noncognate
NatB (Naa20) Nt-acetylase (Fig. 1I and fig. S4,
H and I).
5) Cross-linking and coimmunoprecipitation
experiments indicated that Teb4 interacted with
MQ-Rgs2 (more accurately, with Nt-acetylated
Ac-MQ-Rgs2ha, as shown below) (Fig. 2, H and I).
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Fig. 2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without Teb43f or the MG132
proteasome inhibitor. (B) CHX chases with endogenous MQ-Rgs2, Teb4, and Naa20 subjected to RNAi
for a “scrambled” target, Teb4, or Naa20. The asterisk indicates a protein cross-reacting with anti-Teb4.
(C) Molecular weight standards, purified MQ-Rgs21-10-GST, and purified Ac-MQ-Rgs21-10-GST, respec-
tively. (D) Lane 1, Teb43f input; lanes 2 to 4, GST pull-downs with GST alone, MQ-Rgs21-10-GST, and Ac-
MQ-Rgs21-10-GST, respectively. (E) As in (D) but Coomassie-stained GST fusions released from beads.
(F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb4
C9A
3f . (G) Increases in Teb43f led
to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-Rgs2ha alone (lane 1) or together with
Teb43f (lane 2) were treated with a cell-penetrating cross-linker, followed by immunoprecipitations
with anti-FLAG, reversal of cross-links, SDS–polyacrylamide gel electrophoresis (PAGE), and immu-
noblotting with anti-HA and anti-FLAG. (I) As in (H) but Teb43f alone in lane 1, and i munoprecipi-
tations with anti-HA.
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6) PQ-Rgs2ha was neither Nt-acetylated nor
recognized by the Arg/N-end rule pathway and
was a long-lived protein, in contrast to short-
lived MQ-Rgs2ha (Fig. 1, G and H, and fig. S1C).
In agreement with these in vivo results, Teb43f coim-
munoprecipitated with MQ-Rgs2ha (Ac-MQ-Rgs2ha)
but not with PQ-Rgs2ha (Fig. 2, H and I, and
fig. S3C).
7) Glutathione S-transferase (GST) pull-down
assays showed that Teb4f interacted with Ac-MQ-
Rgs21-10-GST (containing the first 10 residues of
wild-type human Rgs2) but not with MQ-Rgs21-10-
GST or GST alone, indicating that the binding of
Teb4 to Ac-MQ-Rgs21-10-GST required its Nt-acetyl
group (Fig. 2, C to E, and fig. S5B).
By increasing the rate of deactivation of Gaq,
Rgs2 can down-regulate Gaq-activated protein ki-
nases, including the growth-promoting kinase
Erk1/2 (3, 4). We asked whether the Teb4 Ac/N-
recognin could regulate the activation of Erk1/2
through the degradation of Nt-acetylated Ac-
MQ-Rgs2. The Gaq-coupled M3 acetylcholine re-
ceptor was expressed in HeLa cells either alone
or together with MQ-Rgs2ha. By activating the
M3 receptor–coupled Gaq, the agonist carbachol
strongly increased the level of activated Erk1/2
[measured by detecting its phosphorylation by
the “upstream” Mek1/Mek2 kinases (3, 4)].
As predicted by the model in which the Teb4-
Rgs2 circuit regulates the activation of Erk1/2,
this effect of carbachol on Erk1/2 was decreased
in cells that also expressed MQ-Rgs2ha and
was further diminished upon RNAi-mediated
knockdown of Teb4—a change that stabilized
MQ-Rgs2ha and thereby further elevated its lev-
el (Fig. 3C).
Thus, wild-type human Ac-MQ-Rgs2, its
hypertension-associated natural mutants Ac-ML-
Rgs2 and Ac-MR-Rgs2, and its engineered mu-
tant Ac-MK-Rgs2 are conditionally short-lived
physiological substrates of the mammalian Ac/
N-end rule pathway, and the Teb4 ubiquitin li-
gase acts as an Ac/N-recognin of this pathway.
Teb4 promotes G protein signaling by destroy-
ing the Ac-MX-Rgs2 proteins (X =Arg, Gln, Leu),
which are targeted for degradation through
their Na-terminal acetyl group. The faster deg-
radation of ML-Rgs2 and MR-Rgs2 (relative to
wild-type MQ-Rgs2) and their consequently
lower levels can account, at least in part, for the
hypertensive phenotypes of these mutants. The
resulting understanding of Rgs2 with respect
to the N-end rule pathway is summarized in
fig. S6.
Identification of Teb4 as an Ac/N-recognin of
themammalian Ac/N-end rule pathway suggests
that some previously characterized substrates of
Teb4, including specific transmembrane proteins
[(23, 24, 26) and references therein], may be rec-
ognized by Teb4 at least in part though their Nt-
acetylatedNt residues (Ac/N-degrons)—a testable
proposition.
More than 30 human proteins contain anRGS-
type domain (fig. S7) (3, 4). The N-terminal Cys
residue, a common feature of Rgs4, Rgs5, and
Rgs16, can be oxidized in vivo by nitric oxide (NO)
and oxygen. The resulting Nt-arginylation of ox-
idized Cys and the ensuing degradation of these
RGSs by the Arg/N-end rule pathway mediate its
previously described function as a sensor of NO
and oxygen (fig. S1D) [reviewed in (12, 18, 19)].
Our study identified Rgs2 (MQ-Rgs2) as a differ-
ent kind of N-end rule substrate, anNt-acetylated
one. Given their inferredN-terminal sequences, it
is possible, indeed likely, that a number of other
mammalian RGS proteins (in addition to Rgs2,
Rgs4, Rgs5, and Rgs16) may also prove to be
substrates of either the Ac/N-end rule pathway
or the Arg/N-end rule pathway, or both of these
proteolytic systems (fig. S7).
Many cellular proteins contain Ac/N-degrons,
having acquired them during synthesis (13).
These degradation signals, recognized by theAc/N-
end rule pathway, tend to be conditional, owing
to their shielding in cognate protein complexes
(15). In addition, the Ac/N-end rule pathway and
the Arg/N-end rule pathway are functionally com-
plementary (16). It could therefore be possible
to control the levels (and thus the activities) of
many different proteins therapeutically, includ-
ing Rgs2 and other RGSs, by modulating their
Ac/N-degrons or specific components of theAc/N-
end rule pathway.
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Fig. 3. Gaq stabilizes Rgs2 while the Teb4-
mediated degradation of Rgs2 increases sig-
naling by Gaq. (A) CHX chase of MQ-Rgs2ha in
HeLa cells that did not express or overexpressed
the HA-tagged Gaq. (B) Quantification of data in
(A). See the legend to fig. S3 for definitions of
“100%” levels at zero time. (C) HeLa cells were
subjected to RNAi either for a “scrambled” target
or for Teb4. The M3 receptor was transiently ex-
pressed either alone or together with MQ-Rgs2ha.
The levels of indicated proteins, including the levels
of either total Erk1/2 or the activated (specifically
phosphorylated) Erk1/2p, were determined by
SDS-PAGE and immunoblotting of cell extracts
that had been prepared 10 min after treatment of
cells with carbachol.
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6) PQ-Rgs2ha was neither Nt-acetylated nor
recognized by the Arg/N-end rule pathway and
was a long-lived protein, in contrast to short-
lived MQ-Rgs2ha (Fig. 1, G and H, and fig. S1C).
In agreement with these in vivo results, Teb43f coim-
munoprecipitated with MQ-Rgs2ha (Ac-MQ-Rgs2ha)
but not with PQ-Rgs2ha (Fig. 2, H and I, and
fig. S3C).
7) Glutathione S-transferase (GST) pull-down
assays showed that Teb4f interacted with Ac-MQ-
Rgs21-10-GST (containing the first 10 residues of
wild-type human Rgs2) but not with MQ-Rgs21-10-
GST or GST alone, indicating that the binding of
Teb4 to Ac-MQ-Rgs21-10-GST required its Nt-acetyl
group (Fig. 2, C to E, and fig. S5B).
By increasing the rate of deactivation of Gaq,
Rgs2 can down-regulate Gaq-activated protein ki-
nases, including the growth-promoting kinase
Erk1/2 (3, 4). We asked whether the Teb4 Ac/N-
recognin could regulate the activation of Erk1/2
through the degradation of Nt-acetylated Ac-
MQ-Rgs2. The Gaq-coupled M3 acetylcholine re-
ceptor was expressed in HeLa cells either alone
or together with MQ-Rgs2ha. By activating the
M3 receptor–coupled Gaq, the agonist carbachol
strongly increased the level of activated Erk1/2
[measured by detecting its phosphorylation by
the “upstream” Mek1/Mek2 kinases (3, 4)].
As predicted by the model in which the Teb4-
Rgs2 circuit regulates the activation of Erk1/2,
this effect of carbachol on Erk1/2 was d creased
in cells that also expressed MQ-Rgs2ha and
was further diminished upon RNAi-mediated
knockdown of Teb4—a change that stabilized
MQ-Rgs2ha and thereby further elevated its lev-
el (Fig. 3C).
Thus, wild-type human Ac-MQ-Rgs2, its
hypertension-associated natural mutants Ac-ML-
Rgs2 and Ac-MR-Rgs2, and its engineered mu-
tant Ac-MK-Rgs2 are conditionally short-lived
physiological substrates of the mammalian Ac/
N-end rule pathway, and the Teb4 ubiquitin li-
gase acts as an Ac/N-recognin of this pathway.
Teb4 promotes G protein signaling by destroy-
ing the Ac-MX-Rgs2 proteins (X =Arg, Gln, Leu),
which are targeted for degradation through
their Na-terminal acetyl group. The faster deg-
radation of ML-Rgs2 and MR-Rgs2 (relative to
wild-type MQ-Rgs2) and their consequently
lower levels can account, at least in part, for the
hypertensive phenotypes of these mutants. The
resulting understanding of Rgs2 with respect
to the N-end rule pathway is summarized in
fig. S6.
Identification of Teb4 as an Ac/N-recognin of
themammalian Ac/N-end rule pathway suggests
that some previously characterized substrates of
Teb4, including specific transmembrane proteins
[(23, 24, 26) and references therein], may be rec-
ognized by Teb4 at least in part though their Nt-
acetylatedNt residues (Ac/N-degrons)—a testable
proposition.
More than 30 human proteins contain anRGS-
type domain (fig. S7) (3, 4). The N-terminal Cys
residue, a common feature of Rgs4, Rgs5, and
Rgs16, can be oxidized in v vo by nitric ox de (NO)
d oxygen. The resulting Nt-arginyla ion of ox-
idized Cys and the ensuing degradatio of these
RGSs by the Arg/N-end rule pathway mediate its
previously described function as a sensor of NO
and oxygen (fig. S1D) [reviewed in (12, 18, 19)].
Our study identified Rgs2 (MQ-Rgs2) as a differ-
ent kind of N-end rule substrate, anNt-acetylated
one. Given their inf rredN-terminal sequences, it
is possible, indeed likely, that a number of other
mammalian RGS proteins (in addition to Rgs2,
Rgs4, Rgs5, and Rgs16) may also prove to be
substrates of either the Ac/N-end rule pathway
or the Arg/N-end rule pathway, or both of these
proteolytic systems (fig. S7).
Many cellular proteins contain Ac/N-degrons,
having acquired them during synthesis (13).
These degradation signals, recognized by theAc/N-
end rule pathway, tend to be conditional, owing
to their shielding in cognate protein complexes
(15). In addition, the Ac/N-end rule pathway and
the Arg/N-end rule pathway are functionally com-
plementary (16). It could therefore be possible
to control the levels (and thus the activities) of
many different proteins therapeutically, includ-
ing Rgs2 and other RGSs, by modulating their
Ac/N-degrons or specific components of theAc/N-
end rule pathway.
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Fig. 3. Gaq stabilizes Rgs2 while the Teb4
mediated degradation of Rgs2 increases sig-
naling by Gaq. (A) CHX chase of MQ-Rgs2ha in
HeLa cells that did not express or overexpressed
the HA-tagged Gaq. (B) Quantification of data in
(A). See the legend to fig. S3 f r definitions of
“100%” levels at zero time. (C) HeLa cells were
subjected to RNAi either for a “scrambled” target
or for Teb4. The M3 receptor was transiently ex-
pressed either alone or together with MQ-Rgs2ha.
The levels of indicated proteins, including the levels
of either total Erk1/2 or the activated (specifically
phosphorylated) Erk1/2p, were determined by
SDS-PAGE and immunoblotting of cell extracts
that had been prepared 10 min after treatment of
cells with carbachol.
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6) PQ-Rgs2ha was neither Nt-acetylated nor
recognized by the Arg/N-end rule pathway and
was a long-lived protein, in contrast to short-
lived MQ-Rgs2ha (Fig. 1, G and H, and fig. S1C).
In agreement with these in vivo results, Teb43f coim-
munoprecipitated with MQ-Rgs2ha (Ac-MQ-Rgs2ha)
but not with PQ-Rgs2ha (Fig. 2, H and I, and
fig. S3C).
7) Glutathione S-transferase (GST) pull-down
assays showed that Teb4f interacted with Ac-MQ-
Rgs21-10-GST (containing the first 10 residues of
wild-type human Rgs2) but not with MQ-Rgs21-10-
GST or GST alone, indicating that the binding of
Teb4 to Ac-MQ-Rgs21-10-GST required its Nt-acetyl
group (Fig. 2, C to E, and fig. S5B).
By increasing the rate of deactivation of Gaq,
Rgs2 can down-regulate Gaq-activated protein ki-
nases, including the growth-promoting kinase
Erk1/2 (3, 4). We a k whether th Teb4 Ac/N-
recognin could regulate the activation of Erk1/2
through the degradation of Nt-acetylated Ac-
MQ-Rgs2. The Gaq-coupled M3 acetylcholine re-
ceptor was expressed in HeLa cells either alone
or together with MQ-Rgs2ha. By activating the
M3 receptor–coupled Gaq, the agonist carbachol
strongly increased the level of activated Erk1/2
[measured by detecting its phosphorylation by
the “upstream” Mek1/Mek2 kinases (3, 4)].
As predicted by the model in which the Teb4-
Rgs2 ci cuit regulates the activation of Erk1/2,
this effect of carbachol on Erk1/2 was decre sed
in cells that also expressed MQ-Rgs2ha and
was further diminished upon RNAi-mediated
knockdown of Teb4—a change that stabilized
MQ-Rgs2ha and thereby further elevated its lev-
el (Fig. 3C).
Thus, wild-type human Ac-MQ-Rgs2, its
hypertension-associated natural mutants Ac-ML-
Rgs2 and Ac-MR-Rgs2, and its engineered mu-
tant A -MK-Rgs2 are conditionally short-lived
physiological substrates of the mammalian Ac/
N-end rule pa hway, and the Teb4 ubiquitin li-
gase acts as an Ac/N-rec gnin of this pathway.
Teb4 promotes G protein signaling by destroy-
ing the Ac-MX-Rgs2 proteins (X =Arg, Gln, Leu),
which are targeted for degradation through
their Na-terminal acetyl group. The faster deg-
radation of ML-Rgs2 and MR-Rgs2 (relative to
wild-type MQ-Rgs2) and their consequently
lower levels can account, at least in part, for the
hypertensive phenotypes of these mutants. The
resulting understanding of Rgs2 with respect
to the N-end rule pathway is summarized in
fig. S6.
Ide tification of Teb4 as an Ac/N-recognin of
themammalian Ac/N-end rule pathway suggests
that some previously characterized substrates of
Teb4, including specific transmembrane proteins
[(23, 24, 26) and references therein], may be rec-
ognized by Teb4 at least in part though their Nt-
acetylatedNt residues (Ac/N-degrons)—a testable
proposition.
re than 30 human proteins contai n RGS-
o ain (fig. S7) (3, 4). The N-terminal Cys
resi e, a common feature of Rgs4, Rgs5, and
Rgs16, can be oxidized in vivo by nitric oxide (NO)
and oxygen. The resulting Nt-arginylation of ox-
idized Cys and the ensuing degradation of these
RGSs by the Arg/N-end rule pathway mediate its
previously described function as a sensor of NO
and oxygen (fig. S1D) [reviewed in (12, 18, 19)].
Our study identified Rgs2 (MQ-Rgs2) as a differ-
ent kind of N-e d rule substrate, anNt-acetylated
o e. Given their inferredN-terminal sequences, it
is poss ble, indeed likely, that a number of other
mammalian RGS proteins (in addition to Rgs2,
Rgs4, Rgs5, and Rgs16) may also prove to be
substrates of either the Ac/N-end rule pathway
or the Arg/N-end rule pathway, or both of these
proteolytic systems (fig. S7).
Many cellular proteins contain Ac/N-degrons,
having acquired them during synthesis (13).
These degradation signals, recognized by theAc/N-
end rule pathway, tend to be conditional, owing
to their shielding in cognate protein complexes
(15). In ddition, the Ac/N-end rule pathway and
the Arg/N-end rule pathway are functionally com-
plementary (16). It c uld therefore be possible
to control the levels (and thus the activities) of
many different proteins therapeutically, includ-
ing Rgs2 and other RGSs, by modulating their
Ac/N-degrons or specific components of theAc/N-
end rule pathway.
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Fig. S1. Conditional removal of N-terminal methionine from nascent proteins, their 
N-terminal acetylation, and the N-end rule pathway. 
(A) N-terminal processing of nascent proteins by NĮ-terminal acetylases (Nt-acetylases) 
and Met-aminopeptidases (MetAPs). “Ac” denotes the NĮ-terminal acetyl moiety. M, methionine 
(Met) residue. X and Z, single-letter abbreviations for any amino acid residue. Yellow ovals 
denote the rest of a protein molecule. MetAPs cotranslationally remove N-terminal Met from a 
nascent protein unless the side chain of a residue at position 2 is bulkier than Val, in which case 
Met is retained (12, 34). 
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(B) Functional complementarity between the Arg/N-end rule pathway and the Ac/N-end 
rule pathway for proteins bearing the N-terminal MɎ motif, i.e., unacetylated N-terminal Met 
followed by a bulky hydrophobic (Ɏ) residue. This motif is targeted by the Arg/N-end rule 
pathway (16). Because the Met-Ɏ motif is also a substrate of the NatC Nt-acetylase (Fig. S2), 
Met-Ɏ proteins are usually Nt-acetylated at least in part, thereby acquiring the previously 
characterized Ac/N-degrons (13, 16). Thus, both Nt-acetylated and unacetylated versions of the 
same Met-Ɏ protein can be destroyed, either by the Ac/N-end rule pathway or by the 
“complementary” Arg/N-end rule pathway (16). 
(C, D) The mammalian N-end rule pathway. The main determinant of an N-degron is a 
destabilizing N-terminal residue of a protein. Recognition components of the N-end rule 
pathway, called N-recognins, are E3 ubiquitin ligases that can recognize N-degrons. 
Regulated degradation of proteins or their fragments by the N-end rule pathway mediates 
a strikingly broad range of functions, including the sensing of heme, nitric oxide, oxygen, and 
short peptides; control of protein quality and subunit stoichiometries, including the elimination 
of misfolded proteins; regulation of signaling by G proteins; repression of neurodegeneration; 
regulation of apoptosis, chromosome cohesion/segregation, transcription, and DNA repair; 
control of peptide import; regulation of meiosis, autophagy, immunity, fat metabolism, cell 
migration, actin filaments, cardiovascular development, spermatogenesis, and neurogenesis; the 
functioning of adult organs, including the brain, muscle and pancreas; and the regulation of many 
processes in plants (references (12-14, 16, 18, 20, 35-88) and references therein). In eukaryotes, 
the N-end rule pathway consists of two branches, the Ac/N-end rule pathway and the Arg/N-end 
rule pathway. 
(C) The Ac/N-end rule pathway. This diagram illustrates the mammalian Ac/N-end rule 
pathway through extrapolation from its S. cerevisiae version. As described in the main text, the 
Ac/N-end rule pathway has been identified only in S. cerevisiae (13, 15, 16), i.e., the presence of 
this pathway in mammals and other multicellular eukaryotes was conjectural, until the present 
work. Red arrow on the left indicates the removal of N-terminal Met by Met-aminopeptidases 
(MetAPs). N-terminal Met is retained if a residue at position 2 is nonpermissive (too large) for 
MetAPs. If the retained N-terminal Met or N-terminal Ala, Ser, Thr are followed by 
acetylation-permissive residues, the above N-terminal residues are NĮ-terminally acetylated 
(Nt-acetylated) by ribosome-associated Nt-acetylases (21, 89, 90). Nt-terminal Val and Cys are 
Nt-acetylated relatively rarely, while N-terminal Pro and Gly are almost never Nt-acetylated. 
(N-terminal Gly is often N-myristoylated.) N-degrons and N-recognins of the Ac/N-end rule 
pathway are called Ac/N-degrons and Ac/N-recognins, respectively (12). The term “secondary” 
refers to Nt-acetylation of a destabilizing N-terminal residue before a protein can be recognized 
by a cognate Ac/N-recognin. As described in the main text, the human Teb4 E3 ubiquitin ligase 
was identified, in the present study, as an Ac/N-recognin of the mammalian Ac/N-end rule 
pathway. Natural Ac/N-degrons are regulated at least in part by their reversible steric shielding 
in protein complexes (15, 16). 
(D) The Arg/N-end rule pathway. The prefix “Arg” in the pathway’s name refers to 
N-terminal arginylation (Nt-arginylation) of N-end rule substrates by the Ate1 arginyltransferase 
(R-transferase), a significant feature of this proteolytic system. The Arg/N-end rule pathway 
targets specific unacetylated N-terminal residues. In the yeast S. cerevisiae, the Arg/N-end rule 
pathway is mediated by the Ubr1 N-recognin, a 225 kDa RING-type E3 ubiquitin ligase and a 
part of the targeting apparatus comprising a complex of the Ubr1-Rad6 and Ufd4-Ubc4/5 
holoenzymes (12, 14, 18). In multicellular eukaryotes several functionally overlapping E3 
ubiquitin ligases (Ubr1, Ubr2, Ubr4, Ubr5) function as N-recognins of this pathway. An 
N-recognin binds to the “primary” destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, 
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Tyr, Trp and Ile. In contrast, the N-terminal Asn, Gln, Asp, and Glu residues (as well as Cys, 
under some metabolic conditions) are destabilizing owing to their preliminary enzymatic 
modifications. These modifications include the Nt-deamidation of N-terminal Asn and Gln by 
the Ntan1 and Ntaq1 Nt-amidases, respectively, and the Nt-arginylation of N-terminal Asp and 
Glu by the Ate1 R-transferase, which can also Nt-arginylate oxidized Cys, either Cys-sulfinate or 
Cys-sulfonate. They can form in animal and plant cells through oxidation of Cys by nitric oxide 
(NO) and oxygen, and also by N-terminal Cys-oxidases (19, 44, 52, 59, 61, 91-93). In addition to 
its type-1 and type-2 binding sites that recognize, respectively, the basic and bulky hydrophobic 
unacetylated N-terminal residues, an N-recognin such as Ubr1 contains other substrate-binding 
sites as well. These sites recognize substrates that are targeted through their internal 
(non-N-terminal) degrons, as indicated on the diagram (12). Hemin (Fe3+-heme) binds to the 
Ate1 R-transferase, inhibits its Nt-arginylation activity and accelerates its in vivo degradation. 
Hemin also binds to Ubr1 (and apparently to other N-recognins as well) and alters its functional 
properties, in ways that remain to be understood (43). As shown in the diagram, the unacetylated 
Met of the N-terminal MɎ motif is recognized by both yeast and mammalian Ubr1; this 
capability greatly expands the substrate range of the Arg/N-end rule pathway (16).  
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Fig. S2. Specificities and subunit compositions of NĮ-terminal acetylases 
(Nt-acetylases). 
(A) Substrate specificities of S. cerevisiae Nt-acetylases. “Ac” denotes the NĮ-terminal 
acetyl moiety. The bulk of Nt-acetylases are associated with ribosomes (94, 95). The specificities 
of mammalian Nt-acetylases are similar to those of their yeast counterparts, but an individual 
mammalian genome encodes more than ten Nt-acetylases, in contrast to four in S. cerevisiae. 
Some mammalian Nt-acetylases, such as NatF (its catalytic subunit is called Naa60 (see 
fig. S4H, I)) (22), can Nt-acetylate N-terminal motifs that include Met-Lys or Met-Arg, which 
are rarely if ever Nt-acetylated in S. cerevisiae. This compilation of Nt-acetylases and their 
specificities is derived from data in the literature ((21, 89, 90, 96-108) and references therein). 
(B) Subunits of S. cerevisiae Nt-acetylases. This paper employs the revised nomenclature 
for subunits of Nt-acetylases (109) and cites older names of these subunits in parentheses. 
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Fig. S3. The targeting of MX-Rgs2 proteins by the yeast and human Ac/N-end rule 
and Arg/N-end rule pathways. 
(A) CHX chases with the hypertension-associated mutant human ML-Rgs2ha in 
wild-type, naa30ǻ, ubr1ǻ, and naa30ǻ ubr1ǻ S. cerevisiae.  
(B) As in A but in human HeLa cells with wild-type human MQ-Rgs2ha and 
hypertension-associated mutants MR-Rgs2ha and ML-Rgs2ha. 
(C) HeLa cells expressing MQ-Rgs2ha or PQ-Rgs2ha together with Teb43f were treated 
with a cell-penetrating crosslinker, followed by immunoprecipitations with anti-flag, reversal of 
crosslinks, SDS-PAGE, and immunoblotting with anti-ha and anti-flag (see also Fig. 2H and 
Materials and Methods). Note the coimmunoprecipitation of MQ-Rgs2ha with Teb43f, and the 
absence of coimmunoprecipitation of PQ-Rgs2ha. 
12 
 
(D) Quantification of data in A. 100% corresponded to the zero-time level of ML-Rgs2ha 
in naa30ǻ ubr1ǻ S. cerevisiae. 
(E) Quantification of data in B. 100% corresponded to the zero time level of PQ-Rgs2ha 
in HeLa cells.  
In every set of degradation curves shown in this figure and in the main Figs. 1 and 3, 
100% at zero time was chosen to correspond to the relative initial level of the most slowly 
degraded test protein in a given set. Panel A (quantified in D) and panel B (quantified in E) show 
the results of CHX-chases that were independently carried out counterparts of CHX-chases that 
are shown in the main Fig. 1B (quantified in D) and 1F (quantified in E), respectively. These 
comparisons illustrate qualitative reproducibility of independently generated data (particularly 
the robustly reproduced order of metabolic stabilities of specific test proteins in specific genetic 
backgrounds), which differed in relatively minor aspects of corresponding degradation curves. In 
our extensive experience with repeated CHX-chases and 35S-pulse-chases in either S. cerevisiae 
or HeLa cells, a strictly quantitative reproducibility of independently produced and measured 
chase-degradation patterns remains the aim to be reached. 
(F) Extracts from HeLa cells expressing MQ-Rgs2ha in the presence or absence of 
coexpressed Teb43f or Ͷଷ୤େଽ୅ and in the presence of the MG132 proteasome inhibitor, as 
indicated. MQ-Rgs2ha was immunoprecipitated from extracts using anti-ha antibody, followed 
by SDS-PAGE and immunoblotting with anti-ubiquitin antibody to detect polyubiquitin chains 
linked to MQ-Rgs2, and with anti-flag, anti-ha and anti-tubulin antibodies as well, as shown. 
 
 
  
11 
 
 
 
 
Fig. S3. The targeting of MX-Rgs2 proteins by the yeast and human Ac/N-end rule 
and Arg/N-end rule pathways. 
(A) CHX chases with the hypertension-associated mutant human ML-Rgs2ha in 
wild-type, naa30ǻ, ubr1ǻ, and naa30ǻ ubr1ǻ S. cerevisiae.  
(B) As in A but in human HeLa cells with wild-type human MQ-Rgs2ha and 
hypertension-associated mutants MR-Rgs2ha and ML-Rgs2ha. 
(C) HeLa cells expressing MQ-Rgs2ha or PQ-Rgs2ha together with Teb43f were treated 
with a cell-penetrating crosslinker, followed by immunoprecipitations with anti-flag, reversal of 
crosslinks, SDS-PAGE, and immunoblotting with anti-ha and anti-flag (see also Fig. 2H and 
Materials and Methods). Note the coimmunoprecipitation of MQ-Rgs2ha with Teb43f, and the 
absence of coimmunoprecipitation of PQ-Rgs2ha. 
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Fig. S4. Degradation assays with MX-Rgs2 proteins in HeLa cells subjected to 
RNAi of specific Nt-acetylases and Teb4. 
(A) CHX-chases with endogenous (not overexpressed) MQ-Rgs2 in HeLa cells subjected 
to RNAi-mediated knockdowns of endogenous Teb4 or Naa20 (NatB). 
(B) Same as in A but CHX-chases with transiently expressed (exogenous) MQ-Rgs2ha. 
(C) Relative steady-state levels of exogenous wild-type MQ-Rgs2ha and its MR-Rgs2ha 
and ML-Rgs2ha mutants in HeLa cells transfected with equal amounts of MX-Rgs2ha plasmids. 
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(D) ML-Rgs2ha expressed in HeLa cells in the presence of the coexpressed wild-type 
Teb43f or Ͷଷ୤େଽ୅. Note a strong decrease of ML-Rgs2ha in the presence of wild-type Teb43f but 
not in the presence of its inactive missense mutant Ͷଷ୤େଽ୅. Note also a much lower steady-state 
level of active Teb43f (in comparison to the inactive Ͷଷ୤େଽ୅), owing to the previously described 
self-targeting of active Teb4 for degradation (24). 
(E) Same as in D but with MR-Rgs2ha. 
(F) Quantification of data in C (relative levels of the three MX-Rgs2ha proteins). 
(G) Same as in F but quantification, using qRT-PCR, of the relative levels of mRNAs 
encoding the three MX-Rgs2ha proteins. Standard errors of means (SEMs), with qRT-PCR 
assays in triplicate for each sample, are indicated as well. 
(H) Steady-state levels of transiently expressed (exogenous) MR-Rgs2ha in HeLa cells 
subjected to RNAi-mediated knockdowns of either endogenous Naa60, the cognate (for 
MR-Rgs2ha) NatF Nt-acetylase, or endogenous Naa20, the non-cognate (for MR-Rgs2ha) NatB 
Nt-acetylase. Note the increase in MR-Rgs2ha in response to RNAi of Naa60 but not of Naa20. 
(I) Same as in H but with MK-Rgs2ha, a derivative of wild-type MQ-Rgs2ha not 
encountered, thus far, among human patients, that contained another basic residue at position 2.  
(J) 35S-pulse-chases with MX-Rgs2ha (X=R, Q, L) in HeLa cells.  
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Fig. S5. Mass spectrometric analyses of Nt-acetylation of MQ-Rgs2 and 
MQ-Rgs21-10-[GST]. (A) Wild-type MQ-Rgs2ha purified from human HEK293 cells is Nt-
acetylated. (B) Non-Nt-acetylated (upper panel) and Nt-acetylated MQ-Rgs21-10-[GST] fusion 
(lower panel) purified from E. coli that either lacked or expressed, respectively, the 
Schizosaccharomyces pombe NatB Nt-acetylase (see Materials and Methods). 
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Fig. S6. Rgs2, Teb4, N-terminal acetylation, and the N-end rule pathway. Rgs2 and 
Teb4 are, respectively, a substrate and Ac/N-recognin of the mammalian Ac/N-end pathway. 
Only some Rgs2-regulated processes (including the GĮq-mediated activation of Erk1/2 kinase) 
are shown. Both wild-type MQ-Rgs2 and its hypertension-associated mutant MR-Rgs2 (the 
latter is not shown) are Nt-acetylated and conditionally destroyed by the Teb4-mediated 
Ac/N-end rule pathway. In contrast, another hypertension-associated mutant, ML-Rgs2, is 
targeted by both the Ac/N-end rule pathway and the Arg/N-end rule pathway (see the main text) 
(fig. S1C, D). Some abbreviations: IP3, inositol trisphosphate. DAG, diacyglycerol. 
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Fig. S7. Mammalian RGS proteins as identified or predicted N-end rule substrates. 
Human RGS proteins as identified or possible (predicted) substrates of either the 
Ac/N-end rule pathway, or the Arg/N-end rule pathway, or both pathways at the same time, 
depending on the Nt-acetylation status of a specific RGS protein. See also the main text. 
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Table S1.  S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
JD53 MATD trp1- 63 ura3-52 his3- 200 leu2-3112. lys2-801 (110) 
BY4742 MATD his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems, Inc. 
CHY223 doa10'::kanMX6 in JD53 (13) 
CHY272 naa30'::kanMX4 in BY4742 Open Biosystems, Inc. 
CHY345 ubr1'::LEU2 in BY4742 (16) 
CHY349 naa30'::kanMX4 ubr1'::LEU2 in BY4742 (16) 
CHY367 naa20'::natNT2 in JD53 This study 
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Table S2. Plasmids used in this study. 
Plasmids Descriptions Sources 
pCH12 pET30a Novagen, Inc. 
pCH15 pACYCDuet Novagen, Inc. 
pCH61 pcDNA3.1(+) with ha2 Hwang’s lab collection 
pCH692 p316CUP1 Hwang’s lab collection 
pCH759 Teb4 in pcDNA3.1 myc/His (-) (24) 
pCH760 Teb4C9A in pcDNA3.1 myc/His(-) (24) 
pCH766 MQ-Rgs2ha in pcDNA3(+) (11) 
pCH767 ML-Rgs2ha in pcDNA3(+) (11) 
pCH768 MR-Rgs2ha in pcDNA3(+) (11) 
pCH821 MPQ-Rgs2ha in pcDNA3(+) This study 
pCH879 Teb4f3h in pcDNA3.1 This study 
pCH881 Teb4C9Af3h in pcDNA3.1 This study 
pCH3002 MQ-Rgs2-GST in pACYCDuet This study 
pCH3015 pET30a Qiagen, Inc. 
pCH3025 S. pombe Naa20+-NAA25+ in 
pACYCDuet 
(32) 
pCH3056 MQ-Rgs2-GST in pET30a This study 
pCH3080 MQ-Rgs21-10-GST in pET30a This study 
pCH3132 M3ha2 in pcDNA3.1(+) This study 
pCH5050 MQ-Rgs2ha in pRS316, with PCUP1 This study 
pCH5051 ML-Rgs2ha in pRS316, with PCUP1 This study 
pCH5064 GĮqha2 in pcDNA3.1(+) This study 
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Table S3. Some PCR primers used in this study. 
Name Primer sequences 
OCH1091 5’-CTTGGTACCATG CCA CAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH1100 
5’-
AACCTCGAGCTAAGCGTAATCTGGAACATCGTATGGGTAAGAACC
TGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH1265 
5’-
GGTAAGCTTGACTATAAAGACCATGACGGTGATTATAAAGATCAT
GATATCGATTACAAG-3’ 
OCH1266 
5’-
AATCTTAAGTTAATGATGGTGATGGTGATGAGAACCCTTGTCATC
GTCATCCTTGTAATC-3’ 
OCH1514 5'-TATCTCGAGTCATTTTGGAGGATGGTCGCCACCACC -3' 
OCH3006 5’-TCCCATATGCAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH3013 5’-CGCGGATCCTGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH3015 5’-CGCGGATCCATGTCCCCTATACTAGGTTATTGG-3’ 
OCH3095 
5'-
TCCCATATGCAAAGTGCTATGTTCTTGGCTGTTCAATCCCCTATAC
TAGGTTATTGG-3' 
OCH3178 5’-ACAGGATCCATGACCTTGCACAATAACAGTAC-3’ 
OCH3179 5’-ACATCTAGACAAGGCCTGCTCGGGTGCGCGCTTG-3’ 
OCH5070 5’-CCCGGATCCATGCAAAGTGCTATGTTCTTGGCT-3’ 
OCH5071 5’-CCCGGATCCATGTTAAGTGCTATGTTCTTGGCTGTTCAA-3’ 
OCH5073 
5’-
CCCGAGCTCCTAAGCGTAATCTGGAACATCGTATGGGTAGCTAGC
TGTAGCATGAGG CTCTGTGGTGAT-3’ 
OCH5090 5’-GTCGGTACCATGACTCTGGAGTCCATCATGGCG-3’ 
OCH5091 5’-GCTCTCGAGGACCAGATTGTACTCCTTCAGGTT-3’ 
 
  
 
     
Materials and Methods 
 
Reagents and antibodies 
Cycloheximide, dithiobis(succinimidylpropionate) (DSP; Lomant’s reagent), MG132 and 
complete protease inhibitor cocktail tablet were from Sigma, Thermo Scientific, Calbiochem and 
Roche, respectively. Antibodies to the following antigens were used for immunoblotting and/or 
immunoprecipitation: anti-flag M2 (Sigma, F1804 or Stratagen, 200471), anti-c-Myc-9E10 
(Sigma, M5546), anti-hemaggutinin (ha) tag (Sigma, H9658 or H6958), anti-tubulin (Sigma, 
T5168), anti-Teb4 (Bethyl Laboratories, A304-171A), anti-ubiquitin (Stressgen, SPA-203), 
anti-Naa20 (Nat5) (Santa Cruz Biotechnology, sc-100645), anti-Naa60 (Nat15) (Abcam, 
ab103800), anti-phospho-p44/42 Erk1/2 (Cell Signaling Technologies, Ab9101), anti-p44/42 
Erk1/2 (Cell Signaling Technologies, Ab9102) and anti-Rgs2 (Abgent, AT3628a). Secondary 
antibodies for immunoblotting were HRP-conjugated goat anti-rabbit (Bio-Rad, 170-6515) or 
anti-mouse (Bio-Rad, 170-6516), and either ECL Prime Western Blotting Detection System (GE 
Healthcare) or Clarity Western ECL substrate (Bio-Rad) were used, according to manufacturers’ 
protocols. The following reagents were used for immunoprecipitation and GST-pulldown assays: 
anti-flag M2 affinity gel (Sigma, A2220), Dynabeads Protein A and G (Life Technologies), and 
Glutathione Hicap (Qiagen). For determining the state of NĮ-terminal acetylation 
(Nt-acetylation) of Rgs2, human Rgs2 (purified from the HEK293 cell line) was purchased from 
Origene (TP302781) and analyzed using mass spectrometric (MS) techniques (see below). 
 
Yeast strains, media, and genetic techniques 
The S. cerevisiae strains used in this study are described in Table S1. Standard techniques 
(27, 28) were employed for strain construction and transformation. S. cerevisiae media included 
YPD medium (1% yeast extract, 2% peptone, 2% glucose; only most relevant components are 
cited); SD medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose); and 
synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% 
glucose), plus a drop-out mixture of compounds required by a given auxotrophic strain. The 
S. cerevisiae strain CHY367 (naa20'::natNT2) was constructed using PCR-mediated gene 
targeting (29) and the natNT2 module (30) in the strain JD53 (see Table S1). 
 
Cell culture, transfection and RNA interference 
Human HeLa cell line was grown in Dulbecco's Modified Eagle Medium (DMEM) 
(Ronza) supplemented with 10% fetal bovine serum (FBS) (HyClone) and penicillin 
(100 U/ml)/streptomycin (100 Pg/ml) (HyClone) in a 5% CO2 incubator at 37qC. Transfections 
with DNA plasmids or siRNA oligoribonucleotides were carried out using Lipofectamine-2000 
(Life Technologies) according to the manufacturer’s instructions. For RNA interference (RNAi), 
HeLa cells were seeded on day 1 at 2 × 105cells per well in 6-well cell culture plates (SPL Life 
Sciences, Korea) containing DMEM and 10% FCS. After incubations for 24 hr, cells were 
transfected with 100 nM of either human Teb4 siRNA, or Naa20 siRNA, or Naa60 siRNA, or 
non-targeting (control) siRNA (Santa Cruz Biotechnology, sc-91789, sc-37007, sc-62662, and 
sc-93037, respectively), using Lipofectamin-2000 according to the manufacturer’s instructions. 
 
DNA constructs and primers 
E. coli DH5Į strain was used for cloning and maintaining plasmids (Table S1). Solg 
Pfu-X DNA polymerase (SolGent, Korea) was employed for PCR. The plasmids and PCR 
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primers used in this study are described in Tables S2 and S3, respectively. To express human 
MX-Rgs2 (X=Gln, Leu, Arg) in mammalian cells, we used the pCH766, pCH767 and pCH768 
plasmids, which expressed, respectively, MQ-Rgs2ha, ML-Rgs2ha and MR-Rgs2ha from the PCMV 
promoter and were a gift from Dr. R. Neubig (Univ. of Michigan Medical School, East Lansing, 
MI) (11). To construct pCH821, which expressed PQ-Rgs2ha (MPQ-Rgs2ha), the 
MPQ-RGS2ha-encoding DNA fragment was produced by PCR from the plasmid pCH766 
(Table S2) using the primer pair OCH1091/OCH1100. This fragment was digested with 
KpnI/XhoI and ligated into KpnI/XhoI-cut pCH766.  
To construct the low copy (CEN-based) pCH5050 and pCH5051 plasmids, which 
expressed MQ-Rgs2ha and ML-Rgs2ha in S. cerevisiae from the PCUP1 promoter, the relevant 
Rgs2 DNA fragments were amplified from pCH766 using the primer pairs OCH5070/OCH5073 
and OCH5071/OCH5073, respectively. The resulting PCR products were digested with 
BamHI/SacI and ligated into BamHI/SacI-cut pCH692, a pRS316-based low copy plasmid 
containing the PCUP1 promoter.  
To construct pCH879 and pCH881, which expressed, from the PCMV promoter in 
mammalian cells, the wild-type human Teb4 and its catalytically-inactive mutant Teb4C9A (both 
of them were C-terminally tagged with triple flag plus His6), a DNA sequence encoding the 
above “double” epitope was produced by annealing the complementary primers 
OCH1265/OCH1266 (Table S3). The resulting DNA, encoding triple flag plus His6, was 
digested with HindIII/AflII and ligated into HindIII/AflII-cut pCH759 and pCH760, which 
encoded, respectively Teb4 and Teb4C9A in the pcDNA3.1-myc-His(-) A vector (24). The 
plasmid pCH3056, which encoded full-length MQ-Rgs2 whose C-terminus was fused to GST, 
was constructed by producing, at first, a DNA fragment from pCH766 (Table S2), using PCR 
and the primer pair OCH3006/OCH3013. This fragment was digested with NdeI/BamHI. 
Furthermore, a DNA fragment was produced by PCR from pGEX4T-3 and the primer pair 
OCH3015/OCH1514, followed by digestion of the resulting fragment with BamHI/XhoI. The 
above two fragments were ligated into NdeI/XhoI-cut pET30a, yielding the plasmid pCH3056. 
To construct the plasmid pCH3080, which expressed, from the IPTG-inducible T7lac 
promoter in E. coli, a fusion between the N-terminal 10 residues of MQ-Rgs2 and the GST 
moiety, a DNA fragment was produced by PCR using pCH3056 (Table S2) and the primer pair 
OCH3095/OCH1514 (Table S3). The resulting fragment was digested with NdeI/XhoI and 
ligated into NdeI/XhoI-cut pET30a (Table S2).  
To construct pCH3132 that expressed the human muscarinic acetylcholine receptor M3 
from the PCMV promoter, DNA sequence encoding M3 was PCR-amplified from a human 
HEK293T cDNA library using primer pairs OCH3178/OCH3179. The resulting PCR fragment 
was digested with BamHI/XbaI and ligated into BamHI/XbaI-cut pCH61. To clone pCH5064 that 
expressed the human guanidine-nucleotide binding protein G(q) subunit alpha (GĮq) from the 
PCMV promoter, DNA sequence encoding GĮq was also PCR-amplified from HEK293T cDNA 
library using primer pairs OCH5090/OCH5091. The resulting DNA fragment was digested with 
KpnI/XhoI and ligated into KpnI/XhoI-cut pCH61, yielding pCH5064. Construction details for 
other plasmids are available upon request. All final constructs were verified by DNA sequencing. 
 
Cycloheximide-chase assays and immunoblotting 
For immunoblotting, HeLa cells were lysed by incubating them on ice for 20 min in the 
TLB lysis buffer (1% Triton X100, 50 mM NaCl, 2 mM Na-EDTA, 50 mM Tris-HCl, pH 7.4), 
containing complete protease inhibitor mixture (Roche). After precipitating cell debris by 
centrifugation at 11,200g for 10 min at 4°C, total protein concentrations in the supernatants were 
determined using Bradford or DC protein assay (Bio-Rad). Identical total amounts of protein in 
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each sample were heated at 95°C for 10 min or at 37qC for 15 min (the samples for 
immunoblotting of Teb4 were incubated, instead, at 37qC for 20 min) in 1x SDS-sample buffer, 
followed by Tris-glycine-SDS-10% PAGE or Tris-glycine-4-20% PAGE. For immunoblotting 
analyses of Teb4, protein samples were fractionated by Tris-glycine-SDS-6% PAGE or by 
Tris-glycine-SDS-8% PAGE. Fractionated proteins were electroblotted to Immobilon-P 
membranes (Millipore) using mini-transblot cell (Bio-Rad), and were analyzed by 
immunoblotting with indicated antibodies, followed by secondary antibodies described in the 
first section above. Immunoblots were detected using Clarity Western ECL substrate (Bio-Rad) 
or ECL Plus Western blotting Detection System (GE Healthcare). 
Cychloheximide (CHX)-chase assays with HeLa cells were set up on day 1 at 2 × 105
cells/well in 6- or 12-well cell culture plates (SPL Life Sciences, Korea) containing DMEM and 
10% FCS. After 24-hr incubation at 37°C, the cells were treated with CHX at the final 
concentration of 0.1 mg/ml, harvested by centrifugation at each time point, and lysed in RIPA 
buffer (0.1% NP40, 0.15 M NaCl, 5 mM Na-EDTA, 1 mM dithiothreitol (DTT), 50 mM HEPES, 
pH 7.5, plus the “complete protease inhibitor cocktail” (Roche)). Equal amounts of total protein 
were fractionated by Tris-glycine SDS-4-20 % PAGE, followed by immunoblotting with 
indicated antibodies. In particular, immunoblotting with antibody to D-tubulin was used as a 
loading control for all immunoblotting experiments.  
CHX-chases with S. cerevisiae cells were performed as previously described (13, 15), 
with slight modifications. S. cerevisiae were grown to A600 of 0.8-1.0 at 30qC in selective media 
appropriate for a plasmid(s) carried by a strain. Cells were harvested by centrifugation at 11,200g 
for 1 min and thereafter resuspended in fresh YPD to a final concentration of A600 of 1.0, 
followed by the treatment with CHX at the final concentration of 0.2 mg/ml. At indicated times, 
cell samples (corresponding to 1 ml of cell suspension at A600 of 1) were harvested by 
centrifugation for 1 min at 11,200g, and were resuspended in 0.8 ml of 0.2 M NaOH and 
incubated for 20 min on ice, followed by centrifugation for 1 min at 11,200g. Pelleted cells were 
resuspended in 80 Pl of HU buffer (8 M urea, 5% SDS, 1 mM Na-EDTA, 0.1 M DTT, 0.005% 
bromophenol blue, 0.2 M Tris-HCl, pH 6.8) containing 1x protease inhibitor cocktail “for use 
with fungal and yeast extracts” (Sigma), and heated for 10 min at 70qC. After centrifugation for 
5 min at 11,200g, 10 Pl of supernatant was subjected to SDS-10% PAGE, followed by 
immunoblotting with anti-ha (1:2,000) and anti-tubulin (1:2,000) antibodies. Quantification of 
immunoblotting data was carried out using GelQuantNET 
(http://biochemlabsolutions.com/GelQuantNET.html). 
 
Cycloheximide-chase assays with co-expressed Rgs2ha and GĮqha2 
To determine whether GĮqha2, a C-terminally doubly ha-tagged GĮq, could stabilize 
MQ-Rgs2ha against degradation in HeLa cells, cultures at ~90% confluence in 6-well (35-mm) 
plates were transiently cotransfected with 0.5 ȝg of pCH766 (expressing MQ-Rgs2ha) and 2.5 ȝg 
of either pCH5064 (expressing GĮqha2) or pCH61 (vector alone) per well, in the serum-free Opti-
MEM medium (Gibco). After 5-hr transfection, the medium was replaced by DMEM containing 
10% FBS. After incubation for 24 hr at 37qC, the cells were treated with CHX at the final concen
tration of 0.1 mg/ml, harvested by centrifugation at each time point of a chase, and  
lysed in RIPA buffer (0.1% NP40, 0.15 M NaCl, 5 mM Na-EDTA, 1 mM dithiothreitol (DTT),  
50 mM HEPES, pH 7.5, plus the “complete protease inhibitor cocktail” (Roche)). Equal  
amounts of total protein were fractionated by Tris-glycine SDS-12 % PAGE, followed by  
immunoblotting with anti-ha or anti-tubulin antibodies. Immunoblotting with antibody to  
D-tubulin was used as a loading control for all immunoblotting experiments.  
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35S-pulse-chase assays 
HeLa cell cultures (at ~75% confluence) were transfected with 2.5 ȝg of a plasmid per 
35-mm well, using Lipofectamine-2000 according to the manufacturer’s protocol. 48 hr after 
transfection cells were pulse-labeled for 15 min with [35S]-L-methionine (0.1 mCi/ml, MP 
Biomedicals) in DMEM lacking methionine. CHX and 5 mM unlabeled methionine were then 
added to the final concentration of 0.1 mg/ml and 5 mM, respectively. Cells in an entire 35-mm 
well were lysed at the indicated time points of a chase by rapid scraping into 0.1 ml of TSD 
buffer (1% SDS, 5mM DTT, 50 mM Tris-HCl, pH7.4) and snap-freezing in liquid nitrogen. 
Samples were then heated at 95°C for 10 min and diluted with 10 volumes of TNN buffer 
(0.5% NP40, 0.25M Na Cl, 5 mM Na-EDTA, 50 mM Tris-HCl, pH 7.4) containing the 
“complete protease-inhibitor mixture” (Roche). The amounts of 35S in the 10% CCl3COOH-
insoluble fraction of each sample were then measured by liquid scintillation counting. For 
immunoprecipitation, the samples were adjusted to contain equal amounts of total 35S and then 
added to 20 ȝl of anti-ha agarose (Sigma). Suspensions of beads were incubated by rocking at 
4°C for 2 hr, washed 3 times in TNN buffer, and once in 10 mM Tris-HCl, pH 8.5. Final samples 
were eluted by 30 ȝl of SDS-PAGE sample buffer, including the heating at 95°C for 5 min, 
followed by clarification through centrifugation at 11,200g for 1 min. 10 Pl of each of the 
resulting samples were separated by SDS-4-20% PAGE (Bio-Rad, followed by autoradiography 
using Typhoon 9400 PhosphorImager (GE Healthcare) and quantification of autoradiograms 
with ImageQuant (GE Healthcare). 
 
RNA isolation and quantitative RT-qPCR 
Total RNA was isolated from HeLa cells using an RNeasy Mini kit (Qiagen), according 
to the manufacturer’s instructions. 2 ȝg of total RNA was reverse-transcribed into cDNA with 
oligo-dT as a primer by using Promega cDNA reverse transcription kit. Quantitative real-time 
PCR was performed in 20-ȝl reactions containing 10 ng of the cDNA sample, 50 nM forward 
and reverse primers, and the SYBR Green Master Mix (Applied Biosystems). Primers for human 
Rgs2 and ȕ-actin genes were designed using GenScript Real-time PCR Primer Design tool. 
Reaction mixtures were incubated at 95qC for 10 min, followed by 40 cycles of 95qC for 15 sec 
and 60qC for 1 min. No template control sample was included, to enable detection of RNA 
and/or DNA contamination. Quantification of relative Rgs2 mRNA expression levels was carried 
out using the threshold-cycle difference method (ref. (31) and Applied Biosystems StepOne and 
StepOnePlus Real-Time PCR Systems Getting Started Guide for Relative Standard Curve and 
Comparative CT experiments), with ȕ-actin as a normalization control. The Rgs2 and E-actin 
gene primer pairs for RT-qPCR were OCH5082/OCH5083 and OCH5084/OCH5085, 
respectively (Table S3). 
 
In vivo ubiquitylation assay 
HeLa cells were transfected with pcDNA3.1 (control vector), or CH776 (a pcDNA3.1-
based plasmid expressing MQ-Rgs2ha), or pCH879 (expressing Teb43f) or pCH881 (expressing 
Ͷଷ୤େଽ୅) (Table S2). After 24 hr, transfected cells were treated with 10 ȝM MG132 for 4 hr and 
thereafter lysed with RIPA buffer. Supernatants were immunoprecipitated with a monoclonal 
anti-ha antibody (Sigma), and were washed three times in RIPA buffer. Immunoprecipitates were 
fractionated by SDS-8% PAGE, followed by immunoblotting with anti-ubiquitin and/or rabbit 
polyclonal anti-ha antibodies. 
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RNAi-based Erk1/2 activation assay 
For RNAi (siRNA)-based Teb4 knockdown, HeLa cells (at ~70% confluence) in 6-well 
35-mm plates were transfected with 100 pmol of Teb4-specific siRNA using Lipofectamin 2000 
(Life technologies) for 24 hr. The cells were then co-transfected with 0.5 ȝg of M3 muscarinic 
acetylcholine receptor and 3 ȝg of either MQ-Rgs2ha or control (pcDNA3.1(+)) plasmids per 
well in the serum-free Opti-MEM  medium (Gibco). After 5 hr of transfection, the medium was 
replaced by DMEM containing 10% FBS. After incubation for 48 hr at 37qC, HeLa cells were 
subject to serum starvation in DMEM with 25 mM HEPES (pH 7.2) for 24 hr, followed by 
addition of M3 agonist carbachol (Sigma-Aldrich) for 10 min at the final concentration of 
0.1 mM. Agonist-stimulated cells were washed twice in ice-cold phosphate-buffered saline (PBS) 
and thereafter lysed in RIPA buffer containing complete protease inhibitor cocktail (Roche) and 
phosphatase inhibitor mixture (Roche). Cells were then scraped into lysis buffer on ice and a 
lysate was clarified cell by centrifugation at 11,200g for 20 min at 4qC. Equal amounts of total 
protein in 1x SDS-sample buffer were heated at 95qC for 5 min, followed by SDS-10% 
Tris-glycine PAGE, and electrophoretic transfer onto PVDF membranes. The membranes were 
blocked for 1 hr at 4qC in PBS buffer containing 0.1% Tween 20 and 3% bovine serum albumin 
(Sigma-Aldrich), followed by immunoblotting with anti-phospho Erk1/2 or anti-Erk1/2 
antibodies (Cell Signaling Technologies). 
 
Chemical crosslinking and coimmunoprecipitation analyses 
For crosslinking/coimmunoprecipitation assays, HeLa cell cultures (at ~75% confluence) 
in 10-cm dishes were co-transfected with 9 Pg of pCH879 (expressing Teb4f3) and 12 Pg of 
either pCH766, or pCH822, or pcDNA3.1 (see above). After incubation for 24 hr, cells were 
treated with MG132 at 10 PM for 4 hr and thereafter with 1 mM Lomant’s reagent 
(dithiobis(succinimidylpropionate (DSP)), a cell-penetrating amino group-specific crosslinking 
reagent. The in vivo crosslinking reaction was carried out on ice for 2 hr and was stopped by the 
addition of 10 mM Tris-HCl (pH 7.5) for 15 min at 25qC to quench unreacted DSP. Cells were 
gently scraped from plates, pelleted by low-speed centrifugation and lysed by resuspending them 
in 1 ml of buffer A (0.5% Triton X100, 0.15 M NaCl, 1 mM Na-EGTA, 0.1 mM MgCl2., 10 mM 
HEPES, pH 7.4), plus “complete protease inhibitor cocktail” (Roche)) and incubating on ice for 
20 min. The extracts were centrifuged at 11,200g for 20 min at 4°C and total protein 
concentrations in the supernatants were determined using Bradford assay (Bio-Rad). Samples 
containing 1 mg of total protein were incubated with anti-ha or anti-flag bound IgG Dynabeads 
(Life Technologies) at 4qC for 16 hr and the magnetic beads were washed 3 times in buffer A. 
Captured proteins were eluted in 15 Pl of 0.1 M glycine-HCl (pH 2.8), followed by incubation in 
SDS-sample buffer containing 50 mM DTT for 30 min at 37qC, SDS-10% PAGE and 
immunoblotting with anti-ha or anti-flag as described above. 
 
Purification of MQ-Rgs23-10-[GST] and GST-pulldown assays 
To produce and purify the conditionally NĮ-terminally acetylated (Nt-acetylated) 
MQ-Rgs23-10-[GST] fusion, we employed an E.coli-based expression system. “Wild-type” 
E. coli very rarely Nt-acetylates heterologous eukaryotic proteins. In the resulting novel system, 
MQ-Rgs23-10-[GST] was expressed in E. coli either by itself or together with the cognate 
(Nt-acetylating the Met-Gln N-terminal sequence) NatB Nt-acetylase complex from the fission 
yeast Schizosaccharomyces pombe (32). The plasmid pCH3080, expressing MQ-Rgs23-10-[GST], 
was transformed into E. coli BL21(DE3) that carried either a vector plasmid (pACYCDuet 
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(pCH15)) or pCH3025 (32), which expressed the Naa20 and Naa25 subunits of the S. pombe 
NatB Nt-acetylase in E. coli. 
Overnight cultures (5 ml) of transformed E. coli were inoculated into LB medium 
(500 ml) containing chloramphenicol (34 Pg/ml) and kanamycin (50 Pg/ml), followed by growth 
at 37qC to A600 of ~0.7. Expression of MQ-Rgs23-10-[GST] was then induced with 1 mM 
isopropyl E-D-thiogalactoside (IPTG) at 30qC for 4 hr. Cells were harvested by centrifugation 
and frozen at -80qC. Cell pellets were thawed and resuspended in STE buffer (0.1 M NaCl, 
1 mM Na-EDTA, 10 mM Tris-HCl, pH 8.0) containing 1 mM DTT, 1mM phenylmethylsulfonyl 
fluoride (PMSF) and 1 mg/ml of chicken egg white lysozyme (Sigma). Cell suspensions were 
incubated on ice for 20 min and thereafter treated by sonication for 1 min 3 times, at 1-min 
intervals, followed by the addition of Triton X100 to the final concentration of 1%. After 
centrifugation at 11,200g for 20 min at 4qC, the supernatants (~25 ml) were incubated with 1 ml 
of Glutathione Hicap agarose (50% slurry; Qiagen) at 4qC for 2 hr. The beads were washed twice 
in 25 ml of the STE buffer. Carrier-bound GST or MQ-Rgs23-10-[GST] were eluted with 1 ml of 
STE buffer containing 10 mM glutathione (GSH), followed by overnight dialysis against storage 
buffer (10% glycerol, 0.15 M NaCl, 10 mM E-mercaptoethanol, 50 mM HEPES, pH 7.5). The 
state of Nt-acetylation of the resulting MQ-Rgs23-10-[GST] fusion proteins was determined by 
MALD-TOF mass spectrometry. 
For GST-pulldown assays, 50 Pg of either GST, or MQ-Rgs23-10-[GST] (expressed in 
E. coli without S. pombe NatB), or (presumably) Nt-acetylated MQ-Rgs23-10-[GST] 
(coexpressed in E. coli with S. pombe NatB) were incubated with 50 Pl of the Glutathione Hicap 
agarose beads in GST-loading buffer (10% glycerol, 0.5 M NaCl, 1% NP40, 1 mM Na-EDTA, 
50 mM Tris-HCl, pH 8.0) at 4°C for 1 hr. The beads were washed once with 0.5 ml of the 
loading buffer and once with 0.5 ml GST-binding buffer (10% glycerol, 0.05% NP40, 50 mM 
NaCl, 50 mM Na-HEPES, pH 7.8). The beads in 0.2 ml-GST binding buffer were thereafter 
incubated at 4°C for 2 hr with 0.25 ml extracts from HeLa cell (2 mg of total protein) that 
expressed C-terminally triple flag-tagged (plus His6-tagged) Teb4. The beads were washed 3 
times in 0.5 ml of GST-binding buffer, followed by elution of bound proteins by the addition of 
15 Pl of 2xSDS-sample buffer and incubation for 30 min at 37qC. The resulting samples were 
fractionated by SDS-8% PAGE and analyzed by immunoblotting with anti-flag antibody. The 
blotting membrane was also stained with Coomassie Brilliant Blue to verify the approximate 
equality of total protein loads vis-à-vis GST, MQ-Rgs23-10-[GST] and Ac-MQ-Rgs23-10-[GST]. 
 
Analysis of endogenous MQ-Rgs2 from human cells by mass spectrometry 
Purified human Rgs2 (~ 0.4 Pg; see the first section of Materials and Methods) was 
treated with 8 M Urea in 25 mM NH4HCO3 (pH 8.0) and thereafter reduced with 9.5 mM DTT in 
25 mM NH4HCO3 (pH 8.0) at 25qC for 1 hr. Rgs2 was then alkylated with iodoacetamide (32 
mM) in NH4HCO3 (pH 8.0) at 25qC for 1 hr in the dark, followed by quenching of excess 
unreacted iodoacetamide with DTT (40 mM) at 25qC for 10 min. The sample was diluted 10-fold 
with 25 mM NH4HCO3 (pH 8.0), and 1 ml of the resulting sample was digested with of trypsin 
(1.2 Pg/ml) overnight at 37°C. Nt-acetylated peptides in the digested sample were analyzed by 
nanoflow liquid chromatography-tandem mass spectrometry (LC-MS/MS) using the LTQ 
Orbitrap Velos (Thermo Scientific) hybrid mass spectrometer. Nt-acetylation sites were assigned 
by manual inspection of MS/MS spectra and also using MaxQuant software (33). 
 
 
  
